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Abstract 
Aim:  
To evaluate the role and utility of acute kidney injury biomarkers in renal 
transplantation. 
Method:  
Analysis of levels of a panel of biomarkers in deceased organ donors correlated to 
renal graft outcome; ABO incompatible renal transplant recipients correlated to 
rejection and HLA incompatible renal transplant correlated to rejection.  
Results:  
The panel of biomarkers showed comparable ability to creatinine in predicting the 
outcome of the renal graft following transplant from deceased donors. Of the panel 
of biomarkers tested to predict rejection, notably NGAL and IP-10 had good ability 
to predict those HLAi recipients who subsequently developed rejection. 
Conclusion: 
Biomarkers previously identified in the context of AKI may have a role in the 
assessment of deceased organ donor suitability but more promisingly have an 
excellent ability to identify those patients at risk of rejection following HLAi 
transplant and would now benefit from evaluation in a wider population prior to 
adoption in a clinical trial.   
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Chapter 1: Introduction 
 
1.1 Historical Background to Renal Transplantation 
Early attempts at renal transplantation were first made in the early 20th century in 
response to the lack of any other treatment modality for end stage renal failure. 
Some of those attempts showed promise, involving transplanting animal kidneys into 
humans, but although urine was produced the kidneys only functioned for an hour 
before ceasing to function and the patient died within 2 weeks (Morris, 1994). The 
first human to human kidney transplant was performed in 1933 by Voronoy in 
Russia. The graft failed within 48hrs, due to mismatches in donor and recipient ABO 
blood groups which were not known about at the time, highlighting the lack of 
knowledge around immunology and blood antigens at the time, (Hamilton and Reid, 
1984).  
The first successful human renal transplant was undertaken in 1954 at the Brigham 
and Women’s Hospital in Boston by Joseph Murray. The transplant was undertaken 
between identical twins and the graft survived without the need for 
immunosuppression (Murray et al., 1958).  
This initial successful transplant worked because it serendipitously bypassed the 
immune barriers, the mechanics of which were poorly understood at that time. 
Despite advances in the understanding of compatibility between individuals 
previously no measures were available to prevent the response that had been 
termed rejection by Medawar and Brent a decade before (Medawar, 1944),  
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Despite the immune response remaining a barrier to transplantation this single 
operation on December 23rd 1954 by Joseph Murray, which successfully 
transplanted a kidney, remains one of the most important achievements in modern 
science, a feat recognised by the award of the Nobel prize to Murray in 1990. 
This accomplishment demonstrated that not only was kidney transplantation 
technically feasible it reinvigorated a field that for over 50 years had met with failure.  
 
1.1.1 Barriers to Transplantation 
The barriers to transplanting incompatible individuals were identified from skin graft 
experiments. It was known that skin grafts transplanted between non-identical mice 
became necrotic and sloughed off rapidly whilst those from identical mice were 
preserved. It was also noted that a second graft was rejected more vigorously 
indicating the presence of an innate and adaptive immune response. This led to 
testing of this response ex vivo and the development of cross matching and 
subsequently mixed lymphocyte reactions. 
 
1.1.2 The Development of Immunosuppression 
Despite the advances in the understanding of tissue compatibility and the 
identification of the major histocompatibility complex, laboratory models of whole 
organ transplantation were still largely unsuccessful (Dausset, 1980). Whilst 
transplants undertaken in animal models, specifically dogs would work briefly, they 
stopped working and were rejected within days until the advent of mechanisms to 
overcome the immune system (Calne, 1960). 
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Following the realisation that the immune system was a key component in the failure 
of renal transplants, efforts were focused on suppression of the immune system.  
Initially this used whole body irradiation which was known to render the patient 
profoundly immunosuppressed (Murray et al., 1960).  The first clinical trial had only 
one success (transplantation between non-identical brothers) and most failures were 
due to bone marrow suppression, agranulocytosis and overwhelming infection.  
The most significant breakthrough in immunosuppression came with the advent of 6-
mercaptopurine and its later derivative azathioprine (Calne, 1960, Schwartz and 
Dameshek, 1959). These agents alone and more importantly, in combination with 
other anti-rejection agents allowed the recipients to delay rejection without rendering 
the recipients severely immune-deficient.   
The combination of improved surgical technique and, perhaps more importantly, the 
development of new immunosuppressive agents or combinations of existing agents 
is responsible for the growth of renal transplantation to current levels. 
 
1.2 Success of Renal transplantation 
Renal transplantation is now highly successful and the gold standard treatment for 
end stage renal failure (ESRF) with graft survival continuing to improve. Currently 
anticipated graft survival in the UK is greater than 94% at 1 year and 88% at 5 years 
(UKTransplant, 2009, 2013).  
The majority of early graft losses are due to surgical complications and sepsis. 
Chronic graft loss occurs at the rate of around 5% of grafts a year and whilst the 
causes of this are not fully understood acute rejection is still important. However; 
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despite the advances in the prevention of acute rejection, it still remains an important 
cause of early transplant failure and, importantly, impacts on the long term function 
of the allograft (Hariharan, 2001). 
 
1.3 Classifying Allograft Rejection 
The understanding of the process of rejection has increased exponentially since the 
early days of transplantation; however, the precise mechanisms underpinning 
rejection have still not been fully elucidated. This increased understanding has 
allowed different characteristics and processes to be used for the classification of 
rejection. 
Broadly, rejection can be divided into either cellular or humoral with cellular rejection 
mediated by lymphocytes and humoral rejection antibody mediated. 
The chronology and mechanism of rejection allows broad categorisation namely; 
hyperacute, acute and chronic or by histological characteristics (Banff criteria). 
 
1.3.1 Hyperacute and accelerated rejection 
Hyperacute or accelerated rejection occurs immediately following transplantation and 
is caused by the presence of preformed anti-donor antibodies against blood group 
antigens or tissue type and complement (thus humoral in nature). Accelerated 
rejection occurs in the first few days following transplantation and is due to 
reactivation of T cells. it is similar and relies on pre-sensitisation with an accelerated 
and aggressive response of sensitised T cells predominately humoral in nature with 
a smaller component being cellular. 
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1.3.2 Acute rejection 
Acute rejection occurs over days to weeks and is due to the primary activation of T 
cells. This process is normally sub-divided into cellular and vascular processes. It is 
currently thought that cellular rejection has less humoral and more cellular 
mechanism, while vascular has more humoral than cellular mechanics. Cellular 
mechanisms are mediated by lymphocytes activated against donor antigens with the 
donor dendritic cells acting as antigen presenting cells. Humoral injury is mediated 
primarily by antibody and complement. The antibodies are either pre-existing or 
formed following transplant against the donor. The presence of pre-formed donor 
specific antibodies has been shown to correlate to poorer graft outcomes (Patel et 
al., 2007). 
 
1.3.3 Chronic rejection 
Chronic rejection occurs over months to years, whilst the multiple components of 
chronic allograft nephropathy (CAN) are both immunological and non-immunological 
factors. Chronic rejection is also composed of both humoral and cellular mechanistic 
factors (Chan).The classification of the mechanism of rejection is vital to the initiation 
of the correct treatment.  The main method used in the histological diagnosis of 
rejection is based upon the Banff criteria. This grades the histological findings based 
on a renal biopsy specimen to indicate the nature of rejection.  
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1.3.4 Banff criteria 
The Banff criteria represents standardised criteria for the histologic diagnosis of renal 
allograft rejection. It developed following a consensus meeting of surgeons, 
nephrologists and pathologists in Banff, Canada in 1991 and until then there had 
been considerable hetereogeneity in the biopsy reporting across different centres. 
The classification is updated regularly. This standardisation also provides a guide for 
therapy and allows standardised endpoints for research purposes. 
Table 1-1: Different classifications of rejection based on the histological features in the Banff 
system (Solez and Racusen, 2013) 
1. Normal 
2. Antibody mediated rejection (AMR) 
a) Acute AMR 
i) Acute Tubular Necrosis-like Complement factor 4 fragment d (C4d+), 
minimal inflammation 
ii) Capillary margination and/or thromboses, C4d+  
b) Chronic Active AMR 
Glomerular double contours and/or peritubular capillary basement membrane 
multilayering and/or intersitital fibrosis/tubular atrophy and/or fibrous intimal 
thickening in arteries C4d+ 
3. Borderline changes: suspicious for T cell mediated rejection, no intimal arteritis, foci 
of tubulitis 
4. T-cell mediated rejection 
a) Acute T-cell mediated rejection 
b) Chronic active T-cell mediated rejection 
Chronic allograft arteriopathy 
5.  Tubular atrophy/interstitial fibrosis, no evidence of specific aetiology 
i) Mild (<25% cortical area) 
ii) Moderate (26-50%) 
iii) Severe (>50%) 
6. Other: changes not considered to be due to rejection 
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1.3.5 Effect of Rejection on Outcome 
Chronic allograft nephropathy (also called interstitial fibrosis/tubular atrophy) has 
become the dominant cause of kidney-transplant failure and represents the step-
wise loss of nephron mass following cumulative smaller injuries. It is characterised 
by the fibrosis, vascular and glomerular damage that occurs in the renal allograft 
following injury and represents the final common pathway for damage (Chapman et 
al., 2005, Nankivell et al., 2003). Recurrent disease is also a cause of progressive 
decline in and ultimately failure of the transplanted kidneys (Hariharan et al., 1999). 
One of the most important determinants of chronic rejection or nephropathy is acute 
rejection which in turn has been shown to be linked to high panel reactive antibody 
(PRA) levels (established by reacting recipient blood to that of 100 donors to give a 
percentage of the population that the recipient has pre-formed antibodies against), 
long cold ischaemic times and delayed graft function. In one study, recipients of 
deceased transplant who did not experience acute rejection had 5-yr graft survival of 
92% compared to those with one or more episodes of rejection who had an overall 
graft survival of 45% (Kahan, 1993) although it should be noted that newer 
immunosuppressive regimes may have improved this. The precise mechanisms 
underlying the effects of acute rejection on longer term transplant function are not 
fully elucidated however, it appears that late acute rejection and sub-clinical rejection 
are implicated in worse longer term function. This may be because of the “silent” 
nature of the insult as compensatory hyperfiltration by neighbouring unaffected 
nephrons may maintain a stable serum creatinine (Nankivell et al., 2003). 
Therefore it seems intuitive that mechanisms to decrease the incidence of acute 
rejection would impact on graft survival although this has so far not been 
demonstrated (Hariharan et al., 2000). Acute rejection occurring within 0-30, 31-365 
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and >365 days following transplant and adjusted to account for creatinine at the time 
has been shown to give a RR for graft loss of 2.4, 7.1 and 21.8 respectively (Nett et 
al., 2005). The most critical factors for the development of chronic damage following 
acute rejection are the rejection occurring within the first three months, recurrent 
episodes, predominantly vascular rather than interstitial rejection and incompletely 
treated episodes (Leggat et al., 1997).The combination of factors that seem 
associated with the development of CAN are: acute rejection (perhaps through the 
mechanism of causing fibrosis), donor factors, prolonged cold ischaemic time and 
nephrocalcinosis (Schwarz et al., 2005).  
 
1.4 Determinants of outcome in kidney transplantation 
1.4.1 Early vs. Late loss 
It can be seen that rejection, particularly severe rejection, impacts on survival and 
advances in immunological management have improved outcomes, however, it can 
be seen from survival curves that this has been predominately due to early effects, 
that is within the first three months.  
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Figure 1-1 : Long-term survival after first adult kidney only transplant from donors after brain 
death 2000 - 2012 
 
The attrition of kidneys following this has been around five percent per year 
irrespective of the era of immunosuppression. In fact prior to the introduction of 
cyclosporine A, long term survival of kidney transplants on azathioprine 
demonstrated lower attrition rates.  
The reasons for long-term loss of kidneys are multi-factorial but can be broken down 
simplistically into pre-transplant (donor) and post-transplant (recipient) factors and 
these are expanded below. 
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1.5 Donor factors affecting outcome 
1.5.1 Sources of Organs for transplantation 
The landmark first successful transplant was between live donors and until the 
diagnosis of brain stem death criteria were proposed in 1976 it was the main source 
of organs for transplant. With the field of transplantation expanding to other organs 
such as liver (1964 Starzl), pancreas (Lillihei 1966) and heart (Barnard 1967) it was 
recognised that recently deceased donors were the necessary source of vital organs. 
The unmet demand from this source led to live donor kidney transplantation being 
revisited and today both sources are used in large numbers. Both deceased donors 
and live donors are specifically classified as follows. 
 
1.5.1.1 Deceased donors 
Within the deceased donor pool there exist two broadly different groups of donors. 
These are the donation after brainstem death (DBD) donors and the donation after 
circulatory death (DCD) donors. These donors can further be sub-divided into 
standard criteria and extended criteria donors.  
 
1.5.1.1.1 Donation	  after	  Brainstem	  Death	  donors	  
DBD donors are those in whom a diagnosis of brainstem death has been made. The 
donor is then legally determined to be deceased and organ donation proceeds in a 
controlled manner with the patients circulation and respiratory systems supported 
until organ perfusion is established.  
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The process of brainstem death places enormous physiological strain on the body. 
At the point of brain death the brainstem is compressed leading to the Cushing reflex 
which comprises bradycardia and hypertension (Cushing, 1902). This is then 
followed by an autonomic storm driven by massive catecholamine release. These 
factors lead to increased systemic vascular resistance followed by loss of vascular 
tone, hypotension, endocrine organ damage, cellular metabolism derangement and 
blood shunting leading to end-organ hypoperfusion (Eicbaum and Bissetti, 1971). 
This process also causes massive inflammatory activation and cytokine release 
(Vergoulas et al., 2009) with significant increases in inflammatory cytokines including 
IL-6, IL-10, TNF-α, TGF-β and MIP-1a in the brain dead donor group when 
compared to the live donors. Such is the effect of this immune activation that it has 
been linked to more severe ischaemia reperfusion injury following transplantation 
(Weiss et al., 2007). The effect seems to be great enough that the outcomes from 
live kidney donors who are fully mismatched immunologically do better than 
deceased donors who are a closer immunological match (Nijboer et al., 2004). 
Studies in rats have shown that the duration of haemodynamic instability in the donor 
is also critical to the degree and speed of onset of immune activation. This process 
enhances ischaemia reperfusion injury (the injury that occurs to the organ following 
perfusion after loss of blood supply) and predisposes to acute rejection (Van der 
Hoeven et al., 2003).      
It has been proposed that improving management of the potential donor may help 
mitigate these factors and improve outcomes (Schnuelle et al., 1999).  The main 
principles of donor management are directed towards adequate fluid management, 
minimisation of inotropic support if possible, and minimisation of the effects of 
brainstem injury in inducing diabetes insipidus. High dose vasoconstrictors are 
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avoided because of their detrimental effect on donor organs (Nygaard et al., 1990) 
and their inhibitory effect on pituitary hormone function therefore vasopressin is 
recommended (Kustogiannis et al., 2006). Whilst the effect of specific interventions 
is difficult to determine targeted management has been suggested to result in 
greater procurement and end utilisation of organs (Rosendale et al., 2003). 
DBD donors can be divided into standard criteria donors (SCD) or extended criteria 
donors (ECD). 
ECD donors are those donors aged over 60 or donors 50 – 59 with at least two of 
the following: cerebrovascular accident as cause of death, terminal serum creatinine 
>1.5mg/dl or a history of hypertension (Port et al., 2002).  
One of the principal difficulties that exist with deceased donors is that their complete 
medical history is often unknown and sometimes the effects of the pre-terminal event 
make interpretation of biochemical tests extremely difficult.  
 
1.5.1.1.2 Donation after Circulatory Death (DCD) donors 
DCD donors are classified according to the Maastricht criteria which can be seen 
below, however, most UK DCD donors are category 3 (Koostra et al., 1995). In this 
group of donors there must be circulatory asystole for a period of 5 minutes prior to 
the start of the organ donation operation as the criteria for brainstem death cannot 
be met. As circulation and respiratory support has, by definition, stopped prior to the 
commencement of surgery the operation must then be undertaken swiftly to 
establish replacement of circulatory volume with organ preservation solution to 
ensure that organs are cooled and preserved rapidly.  
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In the last few years there has been a large increase in the number of donation after 
circulatory death donors. This move has been championed to increase organ supply.  
Table 1-2: Maastricht criteria for the classification of DCD donors 
Category 1: Dead on arrival at hospital. 
Category 2: Unsuccessful resuscitation. 
Category 3: Awaiting circulatory death. Patients in whom death is inevitable but who 
do not fulfil brainstem-dead criteria. 
Category 4: Circulatory arrest in brainstem-dead individual. 
Category 5: Unexpected circulatory arrest in a patient on ITU  
 
While DCD patients are not subject to the physiological storm of brainstem death 
they are subject to the process of asystole and the period of physiological instability 
leading up to asystole which may be very variable in length. One group who looked 
at the effect of duration of donor instability prior to asystole determined higher 
primary non function rates in the prolonged instability group but noted that rejection 
rates were higher in the group with shorter duration of instability, however, this was 
based on the results of a single centre and has not been consistent elsewhere 
(Goldsmith et al., 2010).  
Rates of primary non-function and delayed graft function following DCD are higher 
than after DBD however, kidneys that do not experience these problems seem to 
have comparable outcomes to DBD kidneys (Hoogland et al., 2010). Indeed an 
analysis of UK data comparing DCD to DBD outcomes showed no difference in 5 
year graft survival or function (Summers et al., 2010). 
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1.5.1.2 Living Donors 
Living organ donation in the UK follows guidelines from the British Transplantation 
Society and the Renal Association. This covers best practice for all aspects of living 
kidney donation (British Transplantation Society and Renal Association 2005). Living 
donation may be considered between blood relatives, non-genetically related 
relatives, friends and altruistic donation (including both directed altruistic and non-
directed). Prior to donation the donor is assessed extensively to ensure that no 
contraindications to donation exist either because of increased risk of future renal 
problems for the donor themselves and to exclude other health problems that could 
be worsened by the effect of surgery. Kidney function is assessed to ensure that 
sufficient renal reserve exists to tolerate losing a kidney and that no underlying 
kidney disease exists in the donor.  
In the process of live donation usually both donor and recipient operations are 
undertaken in the same hospital and therefore cold ischaemic times are significantly 
lower than for deceased donors.  The mechanism of nephrectomy is also more 
controlled as the patient is usually anaesthetically more stable (being intrinsically fit 
and healthy) and therefore the kidney is unlikely to be subject to the variations in 
blood pressure or to large doses of inotropic or other drugs that might subsequently 
effect the outcome of transplantation.  
 
1.6 The impact of donor type on graft survival 
Live donation has increased the number of kidney donors available and results from 
live donation are superior to DBD or DCD donors due to the combination of these 
factors.  UK registry data from 2013 showed 1yr graft survival between the groups 
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demonstrated rates of 97% for live donors vs. 93% for DBD and 93% for DCD 
donors. UK registry data from 2005-2007 demonstrated5yr graft survival of 89% for 
live donors compared to 85% for DBD and 86% DCD donors (UKTransplant, 2009, 
2013).  
 
1.7 Delayed Graft Function (DGF) 
1.7.1 Definition of DGF 
DGF is mainly a manifestation of acute kidney injury (AKI) within the transplanted 
kidney. AKI, in a non-transplant setting, is defined as a rise in creatinine within 48hrs 
of the precipitating event; the timescale for the manifestation of DGF is less defined. 
DGF is historically defined as the need for dialysis in the first seven days following 
transplantation (Siedlecki et al., 2011), IGF refers to the absence of dialysis in the 
first 7 days but with a creatinine of >3mg/dL on the 5th day following transplant but is 
a less commonly used terminology.  Other definitions have been proposed including 
functional DGF defined as a failure of serum creatinine to decrease by at least 10% 
on 3 successive days during the first week post-transplant, irrespective of dialysis 
requirement. Whilst definitions relating to dialysis requirement inherently are harder 
to apply to pre-emptive transplant recipients it is still the most commonly adopted 
definition, and therefore the definition employed here within. 
 
1.7.2 Pathogenesis of Delayed Graft Function (DGF) 
DGF reflects the impact of ischaemia and the physiological insult that the kidney has 
been subject to in the pathway from donation to implantation and the impact of post-
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implantation factors. In part due to the mechanism of donation, rates of delayed graft 
function are much lower amongst the live donor kidneys, 5-10% (Shoskes and 
Cecka, 1997) when compared to rates of delayed graft function for either DBD or 
DCD kidneys. Overall figures suggest that there is a rise in rates of delayed graft 
function and this may be in part due to increased use of DCD kidneys and expanded 
criteria donors.  
One of the main influences on the development of delayed graft function is the cold 
ischaemic time with a 23% increase in the risk of DGF for every 6hrs of cold 
ischaemia, which has also been shown to be a factor in the subsequent development 
of rejection (Ojo et al., 1997, Pratschke et al., 1999). The precise mechanisms of the 
damage that occurs are not fully elucidated but include the switch from aerobic 
metabolism and the consequent accumulation of reactive oxygen species and “free 
radicals”. 
The development of the mechanisms that trigger DGF in the recipient can also be 
related to the whether the donor is DBD or DCD. The catecholamine and cytokine 
storm that ensues after brainstem death can produce complement activation and 
inflammatory immunological responses within the graft well in advance of organ 
recovery. As such both the length of stay in ITU and the duration of time from 
brainstem death to organ procurement are correlated to the development of DGF 
(Blasco et al., 2007, Giral et al., 2007).The administration of dopamine in this cohort 
has been shown to have some beneficial effect on rates of DGF (Schnuelle et al., 
2004). 
Within the DCD pool, which historically has had the highest rates of DGF, one of the 
main determinants of DGF is the duration of warm ischaemia i.e. the period between 
the withdrawal of therapy and the onset of asystole. During this period the kidney is 
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exposed to anaerobic metabolism and subsequently acute tubular necrosis can 
occur. Following reperfusion peritubular oedema can occur compounding the 
ischaemia and rarely the graft may have primary non-function. Pig models have 
elegantly demonstrated that longer periods of warm ischaemia as seen in DCD 
correlate to the development of DGF (Rojas-Pena et al., 2010). 
 
1.7.3 The impact of DGF 
The early effects, within the first few weeks following transplantation, of DGF are 
oliguria, increased risk of acute rejection and increased allograft immunogenicity. It 
has been suggested that this results from the effects of ischaemic injury in increasing 
expression of MHC class I and II (Perico et al., 2004). It also increases the risk of 
early graft loss and this holds true for both DGF and IGF (Raimundo et al., 2013). 
DGF increases the attrition rate for kidneys and this effect is enhanced by the 
presence of rejection. Data from United Network for Organ Sharing (UNOS) 
demonstrated that, independent of rejection, delayed graft function decreased mean 
graft survival and when combined graft survival was reduced from 9.4 to 6.2 years 
(Shoskes and Cecka, 1997). Similar analysis of the link between delayed graft 
function and death with graft function of 44,630 living donor US registry patients 
demonstrated that DGF was associated with an increased risk of death with a 
functioning graft. 1,3 and 5yr survival being 91.9%, 86.8%, 81.6% in those with DGF 
and 98%, 95.2% and 91.6% in those without DGF, although the mechanism 
underlying this remains unclear (Narayanan et al., 2010).  
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1.7.4 Delayed Graft Function and rejection 
Whilst it is clear that DGF alone impacts on both graft and patient outcomes, as 
demonstrated above, it is more difficult to delineate the combined effect of DGF and 
rejection on graft and patient outcomes. One of the potential pitfalls associated with 
DGF is that its presence may mask acute rejection and as such most units routinely 
biopsy DGF to ensure that acute rejection is not being hidden. Inherently therefore, 
acute rejection may have been present for a few days prior to diagnosis with 
subsequent damage. Individual studies have suggested that the incidence of acute 
rejection in the first year following transplant is higher in those patients with DGF 
(51.9% vs. 33.3%) (Miglinas et al., 2013). In analysis of primary deceased renal 
transplants from US data the combination of both DGF and acute rejection led to 
poor 5 year survival of only 35% (Ojo et al., 1997). A meta-analysis of studies 
examining DGF suggested higher rates of acute rejection in the first year following 
transplant in those patients with DGF (49%) as opposed to those without (35%) 
perhaps suggesting a mechanistic link (Yarlagadda et al., 2009). 
 
1.7.5 Acute Kidney Injury in the donor and Delayed Graft Function 
AKI in the organ donor has many definitions e.g. doubling of admission serum 
creatinine, terminal creatinine over 1.5mg/dL. Whilst the presence of donor AKI 
seems to correlate to higher incidence of DGF in recipients this does not seem to 
confer worse longer term outcome (Farney et al., 2013). Indeed one analysis 
demonstrated comparable outcomes in terms of graft survival and renal function at 1 
year between SCD and ECD donors with or without AKI (Klein et al., 2013) however, 
the effect on longer term function has yet to be demonstrated. Historically the 
presence of AKI in a potential organ donor has led to a reticence to accept the 
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organs for transplantation, however, the recognition that AKI may not necessarily 
translate into inferior outcomes has led to an increase in utilisation of kidneys from 
donors with higher terminal serum creatinine. Outcomes from these donors seem to 
show comparable long term function although rates of DGF are higher (Jung et al., 
2013, Farney et al., 2013). 
 
1.7.6 Predictors of DGF 
A number of clinical factors have been identified as predictors of delayed graft 
function. These include factors relating to procurement such as: kidneys from DCD 
donor, inotropic support of the donor, cold storage preservation of the graft and the 
duration of cold ischaemic time and factors relating to the donor such as: age over 
55 and marginal kidneys from hypertensive donors. Recipient factors for example 
recipient hypovolaemia, number of prior transplants, inherited thrombophilia and 
ureteric obstruction. These factors have been combined, weighting attributed and 
many nomograms are available for determining the likelihood of developing DGF 
taking into account both recipient and donor factors however, this remains an inexact 
science. One such nomogram is demonstrated below demonstrating which factors 
and their weighting contribute to predicting the likelihood of DGF. This set of criteria 
was established following analysis of 19,706 deceased recipients and their outcomes 
in US registry data (Irish, 2003). 
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Figure 1-2: Nomogram for predicting the likelihood of delayed graft function in adult 
deceased transplant recipients (Irish, 2003) 
 
1.7.7 Interventions for DGF 
Efforts to ameliorate DGF tend to target the prevention of DGF occurring. From the 
nomogram illustrated above it can be seen that some of the factors implicated in the 
development of DGF can only be influenced by being selective of donor kidneys 
offered, at the expense of potential grafts. Other strategies to prevent DGF have 
looked at ischaemic pre-conditioning in large animal studies with some promising 
early results (Hanto et al., 2010). Efforts to avoid vasoconstriction and its potentially 
deleterious effects have employed the use of endothelin antagonists in animal 
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models and calcium channel blockers which have shown some benefit in the post 
transplant period (Kuypers et al., 2004). Attention has also been focused on 
inhibiting leucocyte adhesion. Similarly the use of induction immunosuppression has 
been shown to decrease the rate of DGF by suppressing leucocyte related vascular 
congestion and resultant endothelial injury (Siedlecki et al., 2011).   
 
1.7.8 Machine perfusion 
The aim of organ preservation and storage following organ retrieval is to prolong the 
potential window of opportunity for transplantation by limiting organ metabolic activity 
and preventing damage to cells within the organ and to ensure the organs are in 
optimal condition. One of the more recent areas of interest in the field of organ 
preservation is the use of machine perfusion. This offers the ability to ensure that the 
organ is properly cooled and circulated with preservation fluid. Dynamic readouts as 
to pressures within the kidney can give a potential indication as to the ‘usability’ of 
the organ. Whilst some studies have suggested a potential benefit, particularly to 
marginal donors (Wight et al., 2003, Treckmann et al., 2011), a prospective trial 
examining their use in DCD donors was halted early due to lack of efficacy (Watson 
et al., 2010). Whilst further research into the role of machine perfusion is on going 
the most recent meta-analysis concluded that there maybe a decrease in the rate of 
DGF in kidneys that undergo machine perfusion prior to implantation (O'Callaghan et 
al., 2012). Whilst research into machine perfusion and its role continues, 
normothermic perfusion has emerged as a potential method of improving donated 
kidneys and shown promising early results (Nicholson and Hosgood, 2013).    
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1.8 Transplantation across immunological barriers 
The matching of donor kidneys to recipients is complex and varied across countries 
and organ sharing schemes. The balance of providing fair and equitable access to all 
recipients whilst ensuring best long term outcomes is based on multiple models 
beyond the scope of this thesis. In the UK the scheme of deceased organ allocation 
is a points based algorithm based predominantly on Human Leukocyte Antigen 
(HLA) matching but also takes into account sensitisation and other factors.  
In living donor transplantation matching is much less specific but historically based 
on blood group compatibility and HLA compatibility.  
Recently these barriers have been crossed using immunoadsorption techniques. The 
drive to cross immunological barriers in renal transplantation arose because of: the 
shortage of donors for renal transplantation; the ever increasing waiting list; and the 
increasing number of patients on the waiting list with high CRF. In 2005 it was 
estimated that in the USA there were approximately 6,000 patients waiting for a 
kidney transplant who had a willing but incompatible live donor (Segev et al., 2005). 
The number of patients on the transplant waiting list with any degree of sensitisation 
in the USA is 25% with 12.5% having a PRA of >80% indicative of those who are 
highly sensitised (Hippen, 2006). These individuals, because of previous 
sensitisation either due to transplantation, pregnancy or previous blood transfusion, 
are likely to have a positive crossmatch.   
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1.8.1 ABO incompatible (ABOi) transplantation 
1.8.1.1 Early ABOi transplantation 
Blood groups, as defined by the antigens on the red cells, were described in the 
early 1900s and have led to the classically known A, B, AB and O system 
(Landsteiner, 1961). The corresponding antibodies produced have hampered 
transplantation since its inception. 
Transplantation across blood group incompatibility in the early days of 
transplantation resulted in universally poor outcomes and was therefore considered 
impossible (Rydberg, 2001). When performed, the histological examination of the 
specimens from these failed transplants showed occluding thrombus of the renal 
artery, reactive neutrophil infiltrates and fibrin deposition at the intima (Wilbrandt et 
al., 1969). These changes were very similar to those seen in hyperacute rejection 
(as it is essentially hyperacute rejection) and it was therefore suggested that that the 
reason ABO incompatible grafts failed was prompt binding of pre-formed circulating 
antibodies to A and B antigens present in the vascular wall of the graft (Porter, 
1976).  
Initial trials of ABO incompatible transplantation involved transplantation from A2 to O 
recipients. The rational for this was that the expression of A antigens on erythrocytes 
from A2 individuals was much weaker than expression in A1 individuals (Economidou 
et al., 1967). This work was then strengthened by skin studies in transplantation 
which demonstrated that skin grafts from A and B donors to O recipients were 
rejected immediately whereas transplants of skin from A2 individuals lasted a 
comparable time to those from O donors (Ceppellini et al., 1969).  Based on this 
initial work a clinical trial was set up which performed 20 transplants from A2 to O 
and A2B to B recipients. Eight of the grafts were lost in the first month, the remaining 
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12 had long term function (Rydberg et al., 1987). Following this titres of anti-A were 
examined and graft survival was shown to be higher amongst those grafts where the 
titre was less than 1:64 (Welsh et al., 1987). 
 
1.8.1.2 Advances in ABO incompatible transplantation 
This has included consensus that splenectomy is not needed as part of the ABOi 
protocol. This is usually in-conjunction with the use of anti B cell depleting anti-CD20 
antibody induction (Rituximab) and with careful monitoring of antibody titres in the 
post-transplant period and implementation of therapy to lower blood group antibodies 
during the initial post-transplant period (Gloor and Stegall, 2007). 
 
1.8.1.3 Outcomes of ABOi transplantation 
From these early experiments ABO incompatible transplantation has rapidly grown 
and is now performed with increasing frequency in transplant centres in North 
America, Europe and Japan. Evaluation of the outcomes from Japanese registry 
ABOi transplantation showed 1, 3, 5 and 10 year graft survival of 86, 82, 74 and 53% 
compared to 96, 89, 81 and 56 in historical controls. However, evolution of protocols 
and more experience has meant that those patient who underwent transplantation 
after 2001 had significantly better outcomes (Takahashi et al., 2006).  
Despite the pre-conditioning that patients undergo as part of the ABOi protocol these 
transplants can still be associated with acute humoral mediated rejection due to 
either a DSA or a blood group specific antibody. A recent randomised control study 
further confirmed that ABO compatible patients with humoral rejection require 
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immunoadsorption and antibody removal and that therapy directed against only 
cellular rejection was inadequate (Bohmig et al., 2007). 
 
1.8.2 HLA incompatible (HLAi) transplantation 
The HLA system is responsible for coding the antigens that are present on the cell 
surface and hence critical for establishing tissue compatibility as they are used to 
determine self from non-self. 
Patients who have been exposed to sensitising factors for example blood 
transfusion, pregnancy or prior organ transplant may develop antibodies that make it 
difficult to achieve a negative cross match prior to organ transplant.  
The seminal paper by Patel and Terasaki in 1969 demonstrated that hyperacute 
rejection can result from transplantation in the presence of preformed donor specific 
anti-HLA antibodies (Patel and Terasaki, 1969). This made a positive cross-match 
an absolute contraindication to transplantation. Current programs have the ability to 
remove donor specific HLA antibodies to achieve a negative crossmatch and 
therefore prevent hyperacute rejection. 
 
1.8.2.1  HLA desensitisation programs 
Careful patient selection is critical for desensitisation programs as the process itself 
is rigorous. The likelihood of successful desensitisation must also be assessed prior 
to initiation as some antibodies prove particularly difficult to remove. Whilst early 
protocols employed the use of routine splenectomy most now utilise plasmapharesis 
or plasma exchange. The exact protocol to achieve desensitisation varies amongst 
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different units and local experience, however, most employ a combination of 
plasmapheresis, low dose IVIG, ATG and maintenance immunosuppression similar 
to standard transplant recipients (Sharif et al., 2012). 
 
1.8.2.2 Outcomes of HLAi transplantation 
However, despite enhanced immunosuppressive protocols rates of rejection remain 
high in this group with subsequent effects on long-term graft function and survival. 
Whilst rates of rejection, graft survival and patient survival differ between groups 
overall they are slightly inferior to standard transplants. Rejection rates vary between 
12-53% of recipients, 2yr patient survival varies between 89-95% and 2yr graft 
survival between 80 and 89% (Gloor et al., 2010, Thielke et al., 2009, Higgins et al., 
2011). 
 
1.9 Monitoring transplant function and biomarkers in current use 
Following renal transplantation in all categories of donor type the monitoring of the 
transplanted organ is essential. Simple clinical parameters such as urine output may 
be used but delayed graft function and native outputs render this as a guide only. 
Biochemical monitoring (using creatinine) is the mainstay using renal function 
although longer term other forms of monitoring may be helpful. 
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1.9.1 Biochemical monitoring 
Laboratory blood tests of renal function routinely rely on urea, creatinine, creatinine 
clearance and estimated glomerular filtration rate (GFR) and these are the current 
“biomarkers” in use. 
 
1.9.1.1 Urea 
Urea is synthesised in the body as part of the urea cycle following oxidation of 
ammonia or amino acids. Urea is produced in the kidney, dissolved in the blood and 
then primarily excreted in the urine. Blood urea nitrogen (BUN) is used a mechanism 
of monitoring renal function, however, its levels are more vulnerable to being 
affected from factors unrelated to the kidney for example upper gastrointestinal 
haemorrhage or heavy protein intake. The reabsorption of urea in the tubules of is 
also variable but may be as high as 40% (Lamb et al., 2005, Traynor et al., 2006). 
 
1.9.1.2 Creatinine 
Creatinine is a break down product of creatine phosphate in muscle. It is produced at 
a fairly constant rate but is dependent on muscle mass. Creatinine is mainly filtered 
by the kidneys and very little is reabsorbed in the renal tubules although some is 
secreted in the proximal tubule. If the filtering mechanism within the kidney is 
defective the level of creatinine within plasma will increase. Whilst a useful measure 
in chronic disease and as a baseline of renal function using alterations to blood 
levels of creatinine as a method for assessing renal damage is flawed.  
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Creatinine is a breakdown product that needs time to accumulate and hence does 
not present a real-time indicator of renal function. For example a rise in creatinine 
normally indicates damage that occurred at least 24 if not 48 hrs prior to the rise. 
This inherently means that the opportunity to intervene and stop the process that has 
led to the rise has been partly missed. The delay actually indicating renal damage 
that has occurred is also reliant on the magnitude or renal injury. Creatinine levels 
remain remarkably stable in kidney injury and will only increase once a significant 
volume of nephron mass has been lost. Therefore in order for creatinine levels to be 
increased a significant mass of the transplanted kidney must be damaged 
(Martensson et al., 2012).  
Creatinine levels are also affected by pre-renal problems such as inadequate 
hydration and may artificially, therefore, be increased and appear to indicate renal 
damage when actually the problem is over concentration and the kidneys 
themselves are functioning normally.  
Plasma creatinine can also be affected by factors that affect degradation of creatine 
phosphate in muscle for example nutrition and infection and may show high inter 
individual variability. Similarly in some conditions because of the comparative 
hypersecretion of creatinine in the proximal tubule the levels of creatinine do not 
accurately reflect the underlying renal function, particularly in glomerulonephritis 
(Shemesh et al., 1985). 
The imprecise and delayed response seen using creatinine would support the use of 
other more rapidly responding and accurate biomarkers of kidney dysfunction 
(Perrone et al., 1992). However, despite the recognised need for improved markers 
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of renal function none have yet completed the transition from research tool to clinical 
utility. 
  
1.9.1.3 Creatinine clearance 
Creatinine clearance is a mechanism of estimating the glomerular filtration rate by 
measuring the urinary creatinine in a set period multiplying it by the volume produced 
and dividing by the serum creatinine. The creatinine clearance tends to overestimate 
GFR due to tubular secretion of creatinine, however, as long as secretion remains at 
a fairly constant rate then changes to renal function can be monitored (Traynor et al., 
2006). Whilst creatinine clearance has a role, in the setting of acute changes in 
transplant function it has limited use due to the necessity to collect urine output for 
24hrs. 
 
1.9.1.4 Estimated GFR (eGFR) 
Many laboratories now routinely report eGFR calculated using the modification of 
diet in renal disease formula (MDRD). This uses the patient’s age, sex, race, serum 
urea, serum creatinine and serum albumin. This provides a good way of estimating 
the renal function in relatively stable patients and has superseded the Cockcroft-
Gault equation as a method of estimating GFR (Cockcroft and Gault, 1976, Levey et 
al., 1999). 
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1.9.1.5 Other methods of detecting renal function 
Inulin is a polymer of fructose that can be administered to achieve a constant blood 
level and then renal excretion and blood levels measured to determine glomerular 
filtration rate. Whilst highly accurate its use lies in research rather than clinical 
practice. 
Radioisotopes can also be administered and their clearance from the blood stream 
calculated to determine GFR. Again these are predominantly used for research as 
they provide very accurate measurements but are too time intensive and laborious to 
incorporate into the dynamic situation immediately post transplant.  
 
1.9.1.6 Other modalities  
Within the context of renal function in the specific transplant population a number of 
other modalities for inferring renal function exist. Following antibody incompatible 
(either HLA or ABO transplantation) titres of antibody can be measured. Whilst these 
do not directly correlate to renal function they are important in monitoring the 
immunological state of the graft. Similarly biopsy of the graft and pathology 
examination of tissue can help monitor the graft for the development of rejection or 
help determine the level of underlying chronic damage.  
 
1.10 Biomarkers in Disease Monitoring 
1.10.1 The Definition of a Biomarker 
A biomarker has been defined by the National Institutes of Health Biomarkers 
definitions working group as: “a characteristic that is objectively measured and 
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evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Group, 2001).” Therefore 
although biomarkers are seen as “new” actually any blood result or indeed clinical 
measurement e.g. blood pressure that is linked to a disease process or normal 
response could be described as a biomarker. Whilst other definitions have been 
proposed there is significant overlap between them (Strimbu and Tavel, 2010). 
 
1.10.2 Characteristics of Biomarkers 
A number of characteristics have been described as being desirable in a biomarker 
(Emerging safety science: Workshop summary, 2008). These will be discussed 
below using Troponin as an example.  
 
• A biomarker should be visible early, prior to histopathological changes and 
should be indicative of active damage. Troponin levels increase within 3-12 
hours following injury, peak at 24-48hrs and return to normal over 5-14 days. 
• A biomarker should be sensitive, but it should also correlate with the severity 
of damage. Troponin has the highest sensitivity and specificity of any marker 
for myocardial infarction and levels have been correlated to the risk of death. 
• The biomarker should be accessible in peripheral tissue and troponin is 
measured in blood. 
• A biomarker should be analytically stable so it can be measured after the 
event as in the case of troponin. 
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• A biomarker should ideally be translational and a bridge across species, and 
troponin has been shown to be useful in other species using drug 
development. 
• The mechanism of the biomarker should be known. Troponin is a contractile 
protein that is only detectable in serum following myocardial necrosis. As a 
biomarker should also be able to localize damage troponin satisfies this 
requirement. 
 
As can be seen Troponin is a very good biomarker, in part explaining its widespread 
usage in clinical practice. 
 
A key element in the evaluation of a biomarker is the sensitivity, specificity, negative 
predictive and positive predictive value. These help interpret how useful a biomarker 
is and the clinical setting in which it will be useful. Whilst an ideal biomarker would be 
highly sensitive and specific in reality many biomarkers are either highly specific or 
sensitive rather than both, however, they still have a clinical role. A very sensitive 
biomarker, e.g. d-dimer in the context of deep vein thrombosis, has a low specificity 
but it very useful in clinical practice as a negative value means it is extremely unlikely 
that the patient has had a deep vein thrombosis. Whilst a high value does not 
specifically relate to any one diagnosis the absence of an elevated level makes it an 
excellent screening test in ruling out a diagnosis.  
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1.10.3 The Evolution of Biomarkers 
The flaws in the currently available markers highlighted above make monitoring the 
renal graft difficult and result in damage occurring before the warning signs are 
apparent. These difficulties in determining true damage within kidneys are not 
confined to renal transplantation but to also determining both acute and chronic 
kidney injury in native kidneys. For these reasons, there has been a drive to 
determine improved techniques of monitoring for renal damage in both native 
kidneys and transplanted kidneys within the renal community in recent years.  
The search for non-invasive biomarkers crosses specialities with examples of 
diagnostic advances in myocardial infarction and deep vein thrombosis. Until the late 
20thcentury the diagnosis of acute myocardial infarction was made on the basis of 
clinical history, electrocardiogram changes and later angiography. However, work 
has led to the identification of cardiac troponin I in 1987 and troponin T in 1989 
(Cummins et al., 1987, Katus et al., 1989). The troponins are structural proteins of 
the cardiac myofilament that are exclusively expressed in cardiomyocytes. Upon 
irreversible cardiac injury troponin T is released and peaks at 24hrs after the insult 
giving vital supportive information to the diagnosis. In deep vein thrombosis, a 
diagnosis with poor clinically documented signs, the use of d-dimers has resulted in 
a non-invasive screening diagnostic test that is not sensitive but is very specific i.e. it 
has a very high negative predictive value. 
 
1.11 Biomarker discovery and application 
As mentioned above a biomarker can be developed from any point from gene 
upregulation to end product. 
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A number of methods exist for the identification of biomarkers including genetic 
studies, genomics, proteomics, metabolomics and microarray techniques. All these 
processes essentially aim to determine molecules that are associated with specific 
disease or pathological processes. Following the identification of biomarkers they 
must then be validated in a variety of populations and settings to establish both the 
sensitivity and specificity of the marker.  
 
1.12 Biomarkers in Renal Disease 
Interest in renal biomarkers has increased due to the recognised problems with 
those currently available and the requirement of invasive methods of diagnosis and 
monitoring that are currently required. 
The kidneys are involved in systemic responses both acute and chronic and may 
represent the overall patients condition for example on intensive care when AKI is 
common but often detected too late. Immunological disease may also affect the 
kidney and diagnosis of renal injury is often late. This obvious need for accurate and 
early screening test for early renal dysfunction, specifically monitoring renal function 
and ideally with prognostic ability for recovery has driven the quest to discover 
biomarkers that may fulfil these roles. Disease specific biomarkers would also be of 
great benefit. In chronic diseases with renal involvement, such as vasculitis, the 
current biomarkers such as ANCA, CRP etc. give disease information but not direct 
information on renal injury.   
A number of potential candidates for biomarkers in renal medicine and renal 
transplantation have been proposed although as yet none have entirely made the 
transition from research to clinical utilisation. The reasons for this are multi-factorial. 
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One of the main problems is that there is not a universally agreed and well 
delineated pathway from discovery to clinical introduction. One of the initial hurdles 
that many biomarkers have faced is that easily employable laboratory methods of 
analysis have been lacking. Even getting through this barrier the scrutiny that is 
placed on newly developed biomarkers is, quite rightly, more rigorous than when the 
currently used methods were introduced.  
 
Those that are applicable to this research are described below. This panel of 
biomarkers were chosen for a number of reasons. As diseases that affect the kidney 
can affect many different areas within the kidney a number of biomarkers are needed 
as some are very specific for certain areas within the nephron. Similarly some of the 
biomarkers were chosen as they reflect the underlying activity within the immune 
system rather than the damage caused. The biomarkers selected represent those for 
which there was good evidence in the literature (as described below) that they may 
have a role in renal transplantation either for monitoring in the recipient or for 
assessment in the potential donor. 
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1.12.1 Kidney Injury Molecule – 1 (KIM-1) 
1.12.1.1 Identification and characteristics 
KIM-1 was first identified following experiments that identified the genes that were 
upregulated following ischaemia in animal studies (Ichimura et al., 1998). It is 
produced in the proximal tubule when the epithelium is induced to dedifferentiate 
following an insult. It is also produced at much lower levels in lymphocytes. 
In normal kidneys KIM-1 is undetectable in urine. Following renal damage, for 
example after an ischaemic insult, the KIM-1 ectodomain is cleaved and it becomes 
detectable in urine. Animal studies have suggested KIM-1 may react more quickly to 
damage than other biomarkers measured (including plasma creatinine, blood urea, 
urinary N-acetyl-B-glucosaminidase (NAG), proteinuria) (Vaidya et al., 2006).  
Currently KIM-1 is measured via lab based research tools such as enzyme linked 
immunosorbent assay (ELISA). The R&D systems ELISA kit has been validated and 
used to show the reference range for the healthy population falls between 59-
2146pg/ml and the assay of detects up to 17ng/ml (Chaturvedi et al., 2009).  
Much of the early research was undertaken using gene expression which would be 
cumbersome in clinical practice. For this reason urinary and serum levels have been 
analysed and shown to correlate to renal KIM-1 expression, the degree of renal 
morphological damage, renal function and proteinuria (van Timmeren et al., 2007b) 
enabling these more easily measured levels to be used in place of gene expression. 
One of the key qualities of any biochemical test is that the analyte to be measured 
has to show a relatively good stability otherwise by the time the sample of urine or 
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blood is analysed the levels will be inaccurate. The stability of KIM-1 has been 
determined under a range of pH ranges and determined that the urinary pH has no 
effect on the stability of KIM-1. However, the measurement of KIM-1 from one of the 
commercially available kits is pH dependent so adjustment of sample to neutral pH 
prior to testing is suggested (Pennemans et al., 2010). 
 
1.12.1.2 KIM-1 in Acute Kidney Injury 
Following the early work that identified KIM-1 as a potential biomarker of renal injury 
its use has been examined in a variety of different settings to establish its potential 
role. Levels of KIM-1 have been shown to be elevated in acute tubular necrosis 
(caused by ischaemia, sepsis) when compared to patients without acute tubular 
necrosis and the expression of KIM-1 has been demonstrated to be confined to the 
proximal tubule (Han, Bailly et al. 2002) suggesting that KIM-1 may have application 
in a wide range of settings.  
A significant cause of renal injury are drugs but both in drug development and 
following exposure to potentially nephrotoxicant drugs detecting the injury early has 
proved challenging. KIM-1 has been shown to act as a marker of injury following 
renal exposure to a range of nephrotoxicants including: Cisplatin and TFEC 
(Ichimura, 2004), cadmium (Prozialeck et al., 2007), mercury, gentamicin and 
chromium (Zhou et al., 2007).  In these studies it has been shown to be sensitive 
and specific and outperform traditional methods of detecting the renal injury. 
Importantly it has also been shown not to react to selective cardiotoxicants and 
hepatotoxicants (Vaidya et al., 2010). KIM-1 has been shown to outperform 
traditional markers of kidney injury in preclinical studies (compared to urea, serum 
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creatinine, NAG) particularly detecting nephrotoxicity before considerable loss of 
renal function occurs and correlating to the degree of histopathological damage 
better. It has been shown to have a role in nephrotoxicants affecting all segments of 
the proximal tubule (Chiusolo et al., 2010).  
KIM-1 levels seem to return to normal in line with recovery of renal function and as 
such KIM-1 is one of a panel of biomarkers that are undergoing FDA approval as 
monitoring mechanisms for drug development (Ozer et al., 2010, Tonomura et al., 
2010). 
One of the challenges faced with AKI is predicting mortality.  Urinary levels of KIM-1 
have been demonstrated to be higher in patients with AKI than without but also to be 
a significant predictor of death or need for dialysis (Liangos et al., 2007, Vaidya et 
al., 2008). 
Cardiac surgery has long carried the risk of AKI and this, in part, explains its high 
associated mortality. It has also been suggested that KIM-1 levels (either individually 
or in combination with other biomarkers) may allow the early detection of 
postoperative AKI in adults after cardiac surgery prior to a rise in serum creatinine. A 
mechanism of early identification could be valuable in instituting strategies to 
minimise the impact of renal dysfunction and to improve patient outcome. A study of 
36 post-operative cardiac surgery patients who developed AKI (defined as a rise in 
serum creatinine >0.3mg/dl within 72hrs of surgery) examined urinary KIM-1, NAG 
and NGAL at five time points over the first 24hrs post operatively. The AUC for KIM-
1 alone to predict AKI was 0.68 immediately post-op and 0.65 3hrs post-op. 
Combining all three biomarkers gave AUC of 0.75 immediately and 0.78 at 3hrs 
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showing promise as a mechanism for directing early treatment in those highlighted 
as likely to develop AKI post-operatively (Han et al., 2009).  
It has been established that one of the best indicators for a poorer outcome following 
hospital admission is the presence of renal dysfunction at presentation and again it 
may be that KIM-1 is sensitive enough to have a role in this setting. A study 
examined admission levels of KIM-1, NGAL and β-2M with comparison to creatinine 
in a paediatric emergency admission centre. The urinary levels of these biomarkers 
detected the presence of AKI and severity more rapidly than creatinine in the acute 
setting, although no severe cases of AKI were seen in the study (Du et al., 2010). 
 
1.12.1.3 KIM-1 in Chronic renal disease 
As mentioned above the monitoring of renal function in chronic disease states, 
particularly systemic diseases, is difficult. Any mechanism that would serve to 
improve this would be welcome. Excretion of KIM-1 has been shown to be higher 
amongst patients with Adult Polycystic Kidney Disease (APKD) when compared to 
controls. KIM-1 has been shown to be positively associated with total renal volume 
independently of albuminuria and a potential role in monitoring disease progression 
has been suggested (Meijer et al., 2010). 
The effect of therapeutic interventions to decrease proteinuria in renal disease on 
KIM-1 levels has been examined. By altering the levels of proteinuria in patients with 
Chronic Kidney Disease (CKD) by medication changes the levels of urinary KIM-1 
decreased in parallel to those of proteinuria. This seems to suggest that modification 
of the treatment leads to amelioration of proteinuria-induced tubular damage. The 
suggestion from the authors is that KIM-1 levels could be used to tailor treatment in 
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patients with CKD and proteinuria to improve outcomes (Waanders et al., 2009, 
Kramer et al., 2009).  
Urinary KIM-1 level has also been shown to have a role in predicting future risk for 
kidney disease independently from albuminuria (Peralta et al., 2012). 
 
1.12.1.4 KIM-1 in kidney donation 
When attempting to assess the potential kidney donor, to determine the underlying 
level of existing renal injury, it seems intuitive that a marker previously suggested to 
be sensitive for AKI might have a role. As such levels of KIM-1 expression have 
been used in small studies to compare the level of renal injury in DBD donors with 
live donors. This work has demonstrated that there is higher expression of KIM-1 
and higher urinary levels of KIM-1 in the DBD group when compared to the live 
donor population. Levels have also shown to be predictive of the recipients 
creatinine at 14 days and at 6 months post transplant (Nijboer et al., 2009, Kamińska 
et al., 2011).   
 
1.12.1.5 KIM-1 in transplant recipients 
Some initial work as to the utilisation of KIM-1 in the monitoring of renal transplant 
function has been undertaken. A cross-sectional study measured 24hr KIM-1 
excretion at a single time point in 606 transplant recipients at a mean of 6yrs post-
transplant and correlated higher levels of KIM-1 positively to graft loss resulting in 
return to dialysis or re-transplantation (adjusted for donor age and creatinine) (van 
Timmeren et al., 2007a). 
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KIM-1 expression in transplant biopsy tissue (indicated both because of rejection and 
protocol driven) showed KIM-1 to be more sensitive than histology in transplant 
biopsies for detecting early tubular injury, correlated to the potential for the kidney to 
recover and sensitively and specifically identified proximal tubule injury (Zhang et al., 
2007).  
KIM-1 expression has also been related to differing causes of renal transplant graft 
dysfunction. Biopsies from patients suffering a) ATN with superimposed rejection, 
(n=21) b) ATN (n=11) c) acute rejection (n=12) d) calcineurin inhibitor nephrotoxicity 
(n=4) and e) interstitial fibrosis and tubular atrophy (n=11) were correlated with levels 
of KIM-1 expression. Levels of KIM-1 expression were highest amongst the 
calcineurin inhibitor nephrotoxicity group and the interstitial fibrosis group and lower 
amongst the ATN and ATN and rejection group (Nogare et al., 2010). 
Urinary KIM-1 has been shown to correlate strongly with creatinine in a group of 
transplant recipients. Levels of KIM-1 were higher amongst those recipients who 
were hypertensive when compared to non-hypertensive recipients and higher 
amongst diabetics than non-diabetics. Levels of KIM-1 amongst all recipients were 
significantly higher than amongst controls (Malyszko et al., 2010).  
 
1.12.1.6 Immunological role of KIM-1 
KIM-1 is also known as TIM-1 (T cell immunoglobulin mucin domains-1) and is 
expressed at low levels by sub-populations of activated T cells. It is also known as 
hepatitis A virus cellular receptor-1 (HAVCR-1) and is expressed by hepatocytes. 
KIM-1 has been shown to co-localize to the site of internalisation of apoptotic cells 
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and mediates this by binding specifically to phosphatidylserine and oxidized lipid 
epitopes on the surface of the apoptotic cell (Ichimura et al., 2008).  
The role of TIM-1/KIM-1 in the regulation of the immune system is not clearly 
defined. However, it seems that TIM-1/KIM-1 may have a role in regulating the 
initiation of phase of T cell response rather than differentiation (Degauque et al., 
2007). It has also been shown that TIM-1/KIM-1 provides a co-stimulatory function 
that affects CD4 T cell function (Umetsu et al., 2005). It has been shown that TIM-
1/KIM-1 blockade by administration of an agonist prevents the induction of 
peripheral-type transplant tolerance in vitro. It is hypothesised that this occurs by 
enhancing the commitment and expansion of alloreactive T cells in the Th1/Th17 T 
effectors, deprogramming natural T regs at the molecular and functional level and 
inhibiting the conversion of regulatory Foxp3+ cells from the naive Foxp3- cells 
(Degauque et al., 2008). It has been shown in experimental models that targeting 
TIM-1/KIM-1 may provide an approach to overcoming resistance to tolerance in a 
cardiac mouse transplantation model (Yuan et al., 2009, Ueno et al., 2008). TIM-
1/KIM-1 blockade has been shown to ameliorate hepatocyte damage in ischaemia 
reperfusion models. This is hypothesised to be through macrophage function in the 
local inflammatory response (Uchida et al., 2010). A study demonstrated that TIM-
1/KIM-1 is a physiological ligand for LMIR-5 and that this interaction is pivotal in 
neutrophil accumulation related to tissue damage in kidney ischaemia reperfusion 
injury. Therefore, it may be that blocking this interaction might be a novel therapeutic 
strategy for acute renal tubular damage (Yamanishi et al., 2010). Mouse models of 
cresenteric glomerulonephritis have shown that blocking KIM-1 can also protect mice 
from proliferative and cresenteric glomerulonephritis via effects on the TH1 and 
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TH17 subsets with concomitant reductions in proteinuria, crescent formation and 
intrarenal leukocyte infiltration (Nozaki et al., 2012).  
 
Whilst KIM-1 has been the subject of intense study in many different fields within 
renal medicine its specific role remains nebulous and its transition to clinical utility is 
still awaited. However, it seems likely that it will make the transition. 
  
1.12.2 Neutrophil Gelatinase Associated Lipocalin (NGAL) 
1.12.2.1 Discovery and characteristics 
Neutrophil gelatinase-associated lipocalin (NGAL) is a member of the lipocalin 
protein family, a large group of small extracellular proteins. These proteins have 
roles in transport, enzyme synthesis, immunomodulation, olfaction, pheromone 
signalling and cell regulation (Flower, 1996).   
NGAL is one of the emerging potential biomarkers for renal injury and is as such 
under intense scrutiny (Haase et al., 2010). Early work utilising genome-wide 
interrogation to identify those genes up-regulated during renal ischaemia models in 
animals identified NGAL as one of the most up-regulated genes (Supavekin et al., 
2003, Mishra et al., 2003).  
 
1.12.2.2 NGAL in AKI 
Initial clinical work involving plasma NGAL utilised the setting of patients post cardio-
pulmonary bypass (CPB) who have a comparatively high incidence of development 
of acute kidney injury. This initial work focused on children for their lack of 
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confounding factors (for example atherosclerosis). A study of 71 children undergoing 
CPB showed 20 children (28%) developed acute kidney injury. In this group the 
diagnosis of acute kidney injury utilising serum creatinine was only possible 1-3 days 
after the surgical insult. However, urine NGAL concentrations rose from a mean of 
1.6ug/l at baseline to 147ug/l 2h after CPB and the serum levels increased from 
3.2ug/l to 61ug/l at 2h after CPB. A significant correlation was shown between acute 
renal injury and urine and serum NGAL 2h after CPB. Using a cut-off value of 50ug/l 
a sensitivity of 1.0 and a specificity of 0.98 was demonstrated (Mishra et al., 2005).  
A US study looked at NGAL in post CPB children to validate NGAL and a rapid point-
of-care Triage NGAL device. Their initial results showed good correlation between 
ELISA and Triage calculated NGAL levels (r=0.94) so a further 120 children were 
enrolled in the study of whom 45 developed AKI. Within this group mean NGAL 
levels increased threefold within 2hrs of CPB surgery and remained elevated 
whereas diagnosis by serum creatinine took 2-3 days. The authors determined that 
for the 2h NGAL level using a cut-off of 150ng/ml a sensitivity of 0.84 and a 
specificity of 0.94 for prediction of AKI. They also determined that the 12h NGAL 
correlated strongly to mortality (Dent et al., 2007). Similar results were generated in 
a study to determine the utility of a standardized clinical platform analyser which 
examined 196 children undergoing CPB of who 99 developed AKI (Bennett et al., 
2008). Other studies seemed to have confirmed the potential utility of NGAL in this 
setting (Wagener et al., 2006, Haase et al., 2009a).  
It has also been suggested that combining NGAL with KIM-1 and NAG (N-acetyl-b-d-
glucosaminidase) could prove useful in detecting early post-operative AKI after 
cardiac surgery prior to a rise in serum creatinine. An improved sensitivity and 
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specificity on combining the biomarkers giving areas under the curve of 0.75 for 
determining immediately and 0.78 at 3h post-op (Han et al., 2009).   
A study in 2008 aimed to determine whether utilising a panel of biomarkers would be 
more sensitive and specific for AKI than an individual biomarker. The underpinning 
theory behind this was that renal structural heterogenicity and the varied causes of 
renal injury may render a single biomarker insufficient. A panel of nine biomarkers 
were examined in 204 patients with and without AKI. Median urinary concentrations 
of each biomarker were higher in patients with AKI than those without. The authors 
applied a logistical regression model to a combination of the markers and 
determined that a combination of specific biomarkers (NGAL, HGF, Protein and KIM-
1) showed greater AUC than individual biomarkers. This suggested that combining 
different biomarkers may move the search forward and help biomarkers make the 
transmission from research to clinically usable measure (Vaidya et al., 2008). 
A study of NGAL in the intensive care examined 451 critically ill patients of whom 
14% developed AKI within 24h and 19% within 48h. Urinary NGAL levels were 
higher among those who developed AKI at 48h than those who didn’t and urine 
NGAL was independently associated with the development of AKI independent of 
age, creatinine, sepsis and illness severity. NGAL demonstrated moderate predictive 
utility for the development and severity of AKI during hospitalisation but as a single 
point measure its utility might be limited (Siew et al., 2009). 
Admission levels of urinary NGAL (and β-2-M and KIM-1) in a paediatric emergency 
setting have been analysed and comparison made to creatinine. Urinary levels of the 
biomarkers detected the presence of AKI and severity more rapidly than creatinine in 
the acute setting, although no severe cases of AKI were seen. 
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NGAL levels have also been studied in septic patients with and without AKI to 
determine whether the presence of sepsis would distort NGAL’s ability to 
demonstrate AKI. A study of patients in intensive care with and without sepsis 
showed that interpretation of plasma NGAL was difficult in the presence of sepsis 
and that urinary NGAL was a better marker in this situation (Mårtensson et al., 2010) 
(Du et al., 2010).  
 
1.12.2.3 NGAL in chronic kidney disease 
A study looking at NGAL in the role of monitoring chronic kidney disease in children 
determined in their sample of 45 children with CKD stage 2 - 4 serum NGAL 
(r=0.62), Cystatin C (r=0.71) and eGFR (r=0.71) were all significantly correlated with 
measured GFR while at lower GFRs serum NGAL (r=0.62) correlated better with 
measured GFR than eGFR or Cystatin C (r=0.41). The authors suggested that NGAL 
may prove useful in the quantification of CKD particularly at lower GFRs (Mitsnefes 
et al., 2006). 
Urinary levels of NGAL have also been correlated to the degree of proteinuria and 
inversely with the residual renal function in patients with primitive membranous and 
membrano-proliferative glomerulonephritis, although the mechanism of the 
correlation could not be determined (Bolignano et al., 2008).   
They have also been shown to be associated with chronic renovascular hypertension 
thought to be due to a combination of on-going kidney and systemic inflammation 
(Eirin et al., 2012). 
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The levels of NGAL and IL-18 have also been studied in the setting of polycystic 
kidney disease in both animal models and human samples. These studies have 
shown that NGAL and IL-18 are elevated in cyst fluid in both human and animal 
models. The levels of NGAL in urine increased in a statistically significant manner 
over a period of 3 years, however, the change in levels did not correlate with total 
kidney function or total kidney volume which the authors surmised could be due to 
the lack of communication between the individual cysts and the urinary collecting 
system (Parikh et al., 2012). They have also been shown to be a marker of renal 
function in diabetic chronic kidney disease however, overall in CKD NGAL has not 
been shown to give more accurate information that GFR (Woo et al., 2012). 
Monospecific assays for NGAL have been demonstrated to correlate with the 
histology in biopsy specimens that typify progressive CKD (Nickolas et al., 2012).  
 
1.12.2.4 NGAL in transplantation 
Urinary NGAL levels were examined prospectively in a cohort of living donor and 
deceased donor renal transplant recipients to determine whether levels were able to 
predict delayed graft function. The group consisted of 23 living donor recipients, 20 
deceased recipients with prompt graft function and 10 deceased recipients with 
delayed graft function. Urine NGAL levels at day 0 was significantly different 
between the 3 groups and highest amongst the delayed graft function group. After 
adjustment for other variables urine NGAL levels on day 0 were shown to predict the 
trend in serum creatinine in the post-transplant period and therefore could have a 
role as an early predictive biomarker for delayed graft function (Parikh et al., 2006). 
A similar study looked at NGAL levels and ability to predict DGF and demonstrated 
day 1 post-operative levels were predictive of dialysis within 1 week of transplant. 
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This predictive ability remained after adjustment for cold ischaemic time, age (donor 
and recipient) and urine output. NGAL also predicted graft recovery at 3 months (Hall 
et al., 2009). Urinary NGAL day 1 post-transplant has also been shown to correlate 
to prolonged DGF that led to poorer graft survival (Hollmen et al., 2010).  
A study looking at serum NGAL levels rather than urine NGAL levels post deceased 
kidney transplant failed to show a difference between serum levels of NGAL between 
the group of patients who experienced delayed graft function and those who had 
immediate or slow graft function (Hall et al., 2011). The expression of NGAL in 
biopsy specimens from renal allografts taken at 0 hour by RT-PCR has also 
demonstrated a 3.78 fold change in NGAL level in the delayed graft function group, 
however odds ratios could not reach significance in the multivariate analysis 
involving donor age. The AUC was 0.75 and suggested that NGAL expression in 0 
hour biopsies has the potential to act as an early biomarker for delayed graft function 
(Korbely et al., 2011).  
Urinary NGAL levels have also been examined to determine whether they can 
differentiate between sub-clinical tubulitis in stable transplant patients and stable 
transplant patients with normal tubular histology to provide a non-invasive 
mechanism for detecting early injury. Whilst significantly higher levels of urinary 
NGAL were seen in a group of patients with clinical evidence of tubulitis NGAL was 
unable to differentiate between the stable patients whether they had sub-clinical 
evidence of tubulitis (Schaub et al., 2007). Similarly in a spot study of 182 patients 
attending clinic NGAL levels in urine were found to be significantly higher in those 
patients with acute allograft rejection even when compared to the other causes of 
AKI. This study determined at a cut-off value of 100ng/ml which demonstrated an 
area under the curve of 0.98 (Heyne et al., 2012). 
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NGAL levels have also been investigated as an early biomarker of graft injury in 
animal models. Porcine kidneys subject to differing degrees of warm and cold 
ischaemia were assessed for levels of NGAL, endothelin-1, IL-6 and TNF-α. Levels 
of NGAL and endothelin-1 were significantly higher in those kidneys exposed to the 
longest periods of warm ischaemia prior to cold storage. The authors suggest that 
NGAL could be used as a marker of the severity of the ischaemic injury sustained 
(Hosgood et al., 2012). 
 
1.12.2.5 Immunological aspects of NGAL 
NGAL has also been shown to be pivotal to the innate immune response to bacterial 
infection via iron sequestering. NGAL limits bacterial growth by sequestering iron-
laden siderophores that are required by many bacteria to grow, this has been 
demonstrated in vivo in NGAL knockout mice who, when infected with Escherichia 
coli H9049, demonstrate substantial increases in bacteraemia and bacterial burden 
(1000 fold greater bacteraemia in NGAL deficient mice). Upon encountering bacteria 
innate immune cells produce and secrete NGAL which limits bacterial growth by iron 
sequestration (Flo et al., 2004).  
The complex generated by the interaction of NGAL with iron binding siderophores 
has also been suggested to convert renal progenitors into epithelial tubules. It has 
therefore been postulated that administration of NGAL could help protect the kidney 
in ischaemia-reperfusion. In a mouse model the administration of NGAL during the 
initial phase of disease (ischaemia-reperfusion) dramatically protected the kidney 
and mitigated azotemia (Mori et al., 2005, Mishra et al., 2004). Whether NGAL 
provides a reservoir to absorb excess iron released from damaged cells preventing a 
   
  
50 
reactive molecule from the site of injury or whether NGAL may recycle iron into 
viable cells stimulating  renal epithelial cells after injury is unclear (Mishra et al., 
2004).  
In order to demonstrate the role of NGAL as a surrogate marker an NGAL reporter 
mouse was created by inserting a double-fusion reporter gene encoding luciferase-2 
and mCherry into the NGAL locus. This mouse then recapitulated and illuminated 
injuries in vivo in real time. A sensitive, rapid, dose-dependent, reversible and organ 
and cell specific relationship with tubular stress was shown. This correlated to the 
level of urinary NGAL (Paragas et al., 2011). 
 
A meta-analysis undertaken in 2009 examined all studies of NGAL in AKI and 
concluded that NGAL level was a useful early predictor of AKI over a range of clinical 
settings. It was concluded that urine or plasma levels were equally useful, that 
standardized clinical platforms using a cut-off of 150ng/ml were superior to research 
assays and that NGAL level had prognostic value for clinical outcomes such as 
progression to renal replacement therapy and mortality (Haase et al., 2009b). For 
this reason it seems likely that NGAL too will make the transition to clinical utility in 
the foreseeable future. 
 
1.12.3 Β-2-microglobulin (β2-M) 
β2-microglobulin (β2-M) is a low molecular weight protein that is detected on the cell 
membrane of all nucleated cells. It is associated with the class-I HLA proteins and 
other membrane proteins. β2-M is freely filtered by the glomerular basement 
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membrane and then reabsorbed and degraded in the proximal tubular cells. It is 
thought that under normal circumstances the levels of β2-M in serum are stable but 
that it is a potential surrogate marker of GFR. For this reason it has been proposed 
as a potential substitute to creatinine. 
As far back as the early 1980’s research was underway to determine whether β2-M 
had a potential role in monitoring the function of renal allografts post-transplantation. 
A study group of 70 deceased transplants and 23 living related transplants showed 
that in those grafts with stable renal function the daily serum levels of β2-M varied 
very little. The study group had 90 episodes of rejection in whom serum β2-M levels 
were significantly elevated at least 1 day prior to the elevation of serum creatinine in 
49% of patients. They felt that serum β2-M was a useful adjunct to the monitoring of 
a renal allograft, particularly as serum β2-M appeared to be cleared by a 
transplanted kidney even in the face of transplant oliguria confirming delayed graft 
function rather than allograft failure (Edwards et al., 1983).  
Following on from this a group in Singapore compared urine β2-M levels in healthy 
subjects with levels in post-renal transplant recipients and demonstrated that 
significant differences existed between the levels of urinary β2-M in the healthy and 
the transplant population and that urine levels of β2-M correlated positively with 
serum creatinine. They also suggested that serum β2-M might have a role in 
differentiating renal function in the transplant population irrespective of creatinine 
(Woo et al., 1985).  
One of the significant limitations of the early work into serum and urine β2-M was 
that the laboratory methods of assessing β2-M were difficult and expensive whereas 
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now β2-M levels can be assessed more readily by relatively easily available routine 
tests such as ELISA. 
These newer methods of measuring β2-M levels reinvigorated research and in 1995 
a group looked at 53 stable renal transplant recipients and compared renal function 
(both serum creatinine and creatinine clearance) and serum β2-M. They also looked 
at 40 healthy individuals and 28 renal donors. All patients included in the study were 
at least 6months post-transplant. They demonstrated a poor correlation between β2-
M and creatinine clearance, although they demonstrated that serum β2-M levels 
were higher in the transplanted patients than either the healthy controls or the 
donors. The authors felt that the reason that despite the excellent allograft function 
the recipients still had elevated levels of serum β2-M even compared to the donors 
who also only had one kidney was due to on-going relationship between the graft, 
the immune system and the immunosuppressive therapy (Pacheco-Silva et al., 
1995).  Having established a correlation between β2-M levels and creatinine the next 
step was to determine whether there was a predictive ability of β2-M levels. Serial 
measurement of β2-M in 46 renal transplant recipients was undertaken and 10 
developed acute rejection. They demonstrated higher mean serum values of β2-M in 
the rejection group as opposed to the group without rejection 6.24 ±0.68mg/l as 
opposed to 4.2 ± 0.23 in the stable function group (p<0.05). The serum creatinine 
between the groups was not significantly different. A β2-M:creatinine ratio of above 4 
at the start of follow up was associated with a relative risk of rejection of 22.9 times 
and a negative predictive value of 89% for rejection and a sensitivity of 70% was 
demonstrated. The authors felt that this measure’s main applicability would probably 
lie in identifying those recipients who would be good candidates for weaning of 
immunosuppression (Saraiva Camara et al., 1998).  
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β2-M serum levels have also been analysed in the context of post-transplant 
infection and shown to be a potential indicator of CMV infection. A study looked at 
sequential serum β2-M levels and correlated them to CMV infection. OF the 18 
cases the group had of CMV 16 patients showed increases in their β2-M levels prior 
to any other indicators of CMV infection. In these cases levels went form a base line 
of 5mg/l to a mean value of 7.7mg/l at the time of diagnosis. This seems to suggest 
that β2-M is a non-specific indicator of problems within the transplant allograft 
(Carvalho Matos et al., 2004).  
Interestingly using modern proteomic methods to identify urine peaks of renal 
allograft rejection suggested β2-M. This group then analysed these urine protein 
peaks and determined that they predominately related to cleaved products from β2-
M. The authors went on to demonstrate that in order for cleavage products of β2-M 
to be produced the urine had to be more acidic and aspartic proteases had to be 
present. They also demonstrated that patients with rejection had more acidic urine 
than those with stable function and healthy individuals (Schaub et al., 2005). In 2006 
a US group used MALDI-TOF MS to analyse urine from 30 renal transplant 
recipients with biopsy proven acute rejection and 15 recipients without rejection. 
They similarly identified β2-M as the peak that most strongly correlated and showed 
a sensitivity of 83.5% and specificity of 80% with a positive predictive value of 89% 
and a negative predictive value of 70.6%. The authors suggested that the real 
application of urine β2-M could lie in combination with other biomarkers (Oetting et 
al., 2006).  
Following on from the increased interest in β2-M in transplantation a Singapore 
group in 2008 aimed to delineate the levels of β2-M in acute renal failure, chronic 
renal failure, stable transplant and renal transplant rejection patients. The study 
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group comprised 23 patients with ARF, 22 patients with CRF, 6 cases of transplant 
rejection and 7 stable transplants and 28 healthy controls. They demonstrated that 
the highest levels of serum β2-M were the chronic renal failure patients (all patients 
had elevated levels, 12.97 +/- 3.83 ug/ml), compared to acute renal failure (all 
patients had elevated levels, 11.75 +/- 2.09ug/ml), transplant rejection (50% had 
moderate elevation, 50% had marked elevation), and compared to stable transplant 
recipients of whom 42.8% had mild elevation of serum β2-M levels. Similarly 21.4% 
of healthy controls were shown to have mildly elevated levels of serumβ2-M. For this 
reason and based on the overlap between each of the groups the authors felt that 
serum β2-M was not superior to serum creatinine (Sonkar et al., 2008). 
In line with research undertaken on other biomarkers urine β2-M has also been 
examined in the context of predicting acute renal failure in those undergoing 
coronary artery bypass grafting in a group of markers. Urine β2-M levels were shown 
to rise in all patients following the stress of surgery with levels resolving after day 1 
post-op but with a second peak of levels at day 3-5 consistent with cleaved products 
that was absent from the group who did not go on to develop acute kidney injury, 
suggesting that they may have a role as predictors of acute kidney injury (Ho et al., 
2009).  
Urinary levels of β2-M have also been demonstrated in animal models to have a 
better diagnostic performance than urea and creatinine for detecting glomerular 
injury. Application has been made based on these animal studies for the use of β2-M 
as part of a panel of biomarkers to assess kidney injury during drug development 
(Dieterle et al., 2010). 
   
  
55 
Whilst research focusing on β2-M levels has been undertaken for nearly 30 years its 
transition from research to bedside test seems to be progressing in combination with 
other biomarkers rather than a stand alone test. 
 
1.12.4 Fractalkine 
Fractalkine is an unusual member of the chemokine family i.e. the chemokines and 
their receptors which exhibit tissue and cellular specificity. As molecules involved in 
the trafficking of cells to tissue sites where receptors are expressed as well as their 
ligands in endothelium they are intrinsically involved in both homeostasis and 
disease and are capable of up and down regulating as required. 
It has three amino acids between the first two cysteine residues and is classified as 
CX3CL1. It exists on the surface of cells and interacts with leukocytes and captures 
cells. It may also be cleaved to produce a soluble form. Expression of CX3CR1 (the 
receptor for Fractalkine) has been demonstrated for T cells, natural killer cells and 
neutrophils. The pathway Fractalkine-CX3CR1 is important in leukocyte trafficking 
and activation and may be important in acute rejection (Imai et al., 1997, Haskell et 
al., 2000). 
This is further implicated when the expression of CX3CR1 in transplant patients with 
acute rejection was examined. In those patients with acute rejection (cellular or 
vascular) higher levels of expression of CX3CR1 were seen than in those patients 
with no biopsy evidence of rejection (Segerer et al., 2002). The role of ligand 
Fractalkine can also be correlated to acute rejection. This study, undertaken in 
China, recruited 215 allograft recipients of whom 67 patients experienced acute 
rejection. In those recipients with stable renal function Fractalkine levels remained 
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stable. Patients with rejection secreted Fractalkine at significantly higher levels than 
patients with no abnormal histological findings. In the same study patients with 
chronic allograft nephropathy and acute tubular necrosis also showed increased 
urinary levels of Fractalkine though significantly lower than those experiencing 
rejection. Higher levels of urinary Fractalkine were also shown to correlate to steroid-
resistant rejection and graft loss at an early stage after acute rejection (Peng et al., 
2008).supporting the role hypothesised for CXC3L1/Fractalkine in the mechanism of 
acute rejection. 
 
 
1.12.5 Cystatin C 
Cystatin C is a non-glycosylated low molecular weight protein that is produced by all 
nucleated cells at a stable rate. Blood concentration therefore should reflect 
glomerular filtration rate (GFR).  
Studies have utilised cystatin C either in combination with other markers (e.g. 
creatinine) and other parameters to try to improve the ability of clinicians to estimate 
GFR. Some studies have shown that using serum cystatin C level as part of a 
formula including serum creatinine proved superior to using creatinine alone (Tidman 
et al., 2007, Ma et al., 2007, Roos et al., 2007). An improvement in calculation of 
GFR has also been demonstrated in cirrhotic liver patients by the inclusion of 
cystatin C (Poge, 2006). However, some authors have raised issues with the use of 
cystatin C in the calculation of GFR amongst transplant recipients and other clinical 
presentations and suggested its use as a GFR measure should be in the chronic 
kidney disease population (Rule et al., 2006). One study looked at the use of cystatin 
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C in comparison to the calculation of GFR using the Modification of Diet in Renal 
Disease (MDRD) equation in renal transplant patients and concluded that they were 
essentially equivalent but that as the availability of the MDRD was superior it should 
be used, although cystatin C could provide a useful adjunct particularly amongst 
those with well-functioning grafts (Poge et al., 2006). In a comparison between 
cystatin C and creatinine one study showed that cystatin C had a greater specificity 
but lower sensitivity than creatinine for detecting dysfunction in transplant patients 
(Tsai et al., 2010). However, despite the developments of the potential inclusion of 
cystatin C, either as a component of the equations or as a separate measure, 
caution is has been advised in interpretation (Hergetrosenthal et al., 2007). 
Confounding factors in the variability of cystatin C levels are multiple and include 
age, male gender, increasing BMI, height, smoking status and higher CRP levels. 
These factors may impact on the interpretation of cystatin C levels (Knight et al., 
2004). It has also been suggested that concurrent glucocorticoid therapy may alter 
cystatin C levels, necessitating the development of specific reference ranges for 
patients receiving immunosuppression including steroids. This may also go part way 
to explaining the differences seen in cystatin C levels between patients with similar 
GFRs but with and without renal transplants (Risch et al., 2001).   
In liver transplantation cystatin C has been shown in a single study to be a sensitive 
marker of post orthoptic liver transplantation kidney function. The authors suggested 
that if the pre-operative cystatin C level exceeded a certain cut-off then a 
deterioration of renal function post-transplant was likely (Nemes et al., 2010). It has 
been shown to have a potential role in the post-operative monitoring of children after 
liver transplant proving significantly more sensitive than GFR calculated using 
creatinine (Brinkert et al., 2010). 
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Serum Cystatin C has also been utilised in monitoring for renal complications during 
drug development in pre-clinical animal models. Cystatin C has been shown to be 
more sensitive and specific than creatinine in monitoring generalised renal function 
in rat nephrotoxicity models (Ozer et al., 2010). As such the FDA has now 
recognised the use of cystatin C as part of a panel of biomarkers for monitoring renal 
safety during drug development (Dieterle et al., 2010).  
Another potential role for cystatin C has been in the early detection of AKI. It has 
been suggested that serum cystatin C can detect AKI up to 48hrs prior to a rise in 
creatinine (Herget-Rosenthal et al., 2004).  
A study in 2008 looked at the possible role of urinary cystatin C in detecting AKI. 
Median urinary concentration of Cystatin C was shown to be significantly higher in 
patients with AKI than those without, however, levels did not correlate to progression 
to renal replacement therapy or death in contrast to previous studies (Herget-
Rosenthal, 2004), (Vaidya et al., 2008). This is in contrast to a study of 200 patients 
with AKI in which serum cystatin C was shown to perform similarly to creatinine for 
predicting dialysis progression or in-hospital death (Perianayagam et al., 2009).  
A further study in 2009 demonstrated a role for cystatin C in AKI following cardiac 
surgery. Levels immediately post-operatively correlated with and independently 
predicted duration and severity of AKI in adult patients (Haase et al., 2009a).  
Similarly, in a study of AKI due to radiographic contrast, cystatin C level at 24hrs 
post contrast media administration rose <10% from baseline then kidney function 
was unlikely to be affected (Briguori et al., 2010) in comparison to those with 
elevated levels who suffered a change to creatinine. Urinary cystatin C has also 
been used in an intensive care setting and is independently associated with AKI, 
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sepsis and death within 30 days (Nejat et al., 2010). This ability to diagnose and 
predict AKI using cystatin C has been improved by stratifying levels according to 
GFR, with AUC for cystatin C with an eGFR<60 of 0.69 at 6 hours after admission to 
ITU and an AUC of 0.88 at 12-36hr being predictive of AKI (Endre et al., 2011).  
Cystatin C has been examined in the context of monitoring of renal transplant 
recipients. In 30 adults receiving renal transplants levels of plasma cystatin C 
correlated to plasma creatinine (r=0.741; p=<0.0001). In those cases of rejection of 
the allograft the increase in plasma cystatin was seen to be more prominent than 
that of creatinine (Le Bricon et al., 1999). This has also been seen in other studies 
(Liu, 2012). 
Serum cystatin C has also been used to predict early graft function after deceased 
donor kidney transplant. In a cohort of 78 recipients of whom 26 had delayed graft 
function and 29 had slow graft function serum cystatin C outperformed serum 
creatinine on the first day post-operatively for predicting the clinical course (area 
under the curve of 0.83 (DGF) and 0.85 (non-immediate graft function) compared to 
0.65 and 0.53 respectively for serum creatinine) (Hall et al., 2011).  
 
1.12.6 Interferon-inducible protein-10 (IP-10) 
IP-10 is a small cytokine that is secreted by several cell types in response to 
interferon-gamma. These include monocytes, endothelial cells and fibroblasts. It 
elicits its response by binding to the cell surface chemokine receptor CXCR3. 
Several roles have been attributed to IP-10 including chemo-attractant, promotion of 
T cell adhesion to endothelial cells, anti-tumour activity, and inhibition of 
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angiogenesis. Studies have also shown that CXCR3 also has a role in mediating 
host alloresponses and graft destruction (Hancock et al., 2000). 
In a US study of 58 renal transplant recipients (of which 27 had acute rejection, 16 
had chronic allograft nephropathy) the levels of IP-10 mRNA in urine predicted 
rejection.  ROC showed that at a (log-transformed) mRNA levels of 9.11 copies 
acute rejection could be predicted with a sensitivity of 100% and a specificity of 78%.  
Urinary expression of IP-10 was absent in grafts with stable function (Tatpudi et al., 
2004). 
A study of IP-10 in urine in 99 transplant recipients was undertaken to determine the 
ability of urinary IP-10 to detect injury. Of the 99 transplants 28 had acute rejection, 9 
had borderline rejection, 6 had BK nephropathy and 10 had acute tubular injury. 
Samples from 16 healthy, non-transplanted individuals were also analysed. 
Quantities of IP-10 in the urine samples were measured by Luminex™ assay. 
Patients with acute rejection, BK virus and acute tubular injury had higher levels of 
IP-10 while stable function and chronic rejection had lower levels. The level of IP-10 
also fell as treatment was instigated for acute rejection with most patients reaching a 
level under 100pg/ml. The authors suggest that IP-10 might have a role as an 
adjunct in deciding whether to biopsy patients but was not individually diagnostic (Hu 
et al., 2004).  
IP-10 has also been correlated to overall graft function. Urinary levels and mRNA 
have been correlated to episodes of rejection, in which increases in IP-10 precede 
rises in serum creatinine, but also levels in the first 4 weeks correlate to outcome of 
the graft at 6 months. Patients with urinary tract infections or CMV infection showed 
no increase in IP-10 levels in urine. The authors suggest that IP-10 expression 
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correlates to specifically intra-graft immune activation that leads to acute rejection 
and that measuring levels of IP-10 might allow stratification of patients on the basis 
of immune risk and therefore allow individual tailoring of immunosuppression (Matz 
et al., 2006).  
IP-10 levels pre-transplant have also been correlated to early severe rejection and to 
chronic allograft nephropathy in serum from 316 graft recipients and in biopsy 
specimens from 22 patients with acute rejection. In this cohort pre-transplant serum 
levels greater than 150pg/ml carried an increased risk for severe acute rejection, 
infact they demonstrated increased pre-transplant levels carried a relative risk of 
2.81 for graft loss (Lazzeri et al., 2005, Rotondi et al., 2004).  
Studies undertaken in cardiac allografts in mice demonstrated that MHC-mismatched 
mice who were transplanted had longer survival times if they were null, i.e. could not 
express, for cxcr3 the receptor for IP-10. This was further extrapolated to 
demonstrate that the use of CXCL10 (IP-10) monoclonal antibody blocking this 
pathway resulted in prolonged survival (Hancock et al., 2000, Hancock et al., 2001). 
 
1.12.7 Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor is a heparin-binding protein with a multitude of 
functions. It was initially described because of its ability to increase vascular 
permeability and stimulate the growth of endothelial cells (Ferrara et al., 1991). It has 
also been found to act as a mediator in inflammation by acting in a chemo-attractant 
manner to monocytes and promoting adhesion (Neufeld et al., 1999). Within the 
kidney VEGF expression is most prominent in the glomerular and peritubular 
endothelial cells. It is needed for glomerular and tubular hypertrophy in response to 
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nephron loss and is associated with glomerulosclerosis and fibrosis within the kidney 
(Schrijvers et al., 2004).  
A study examined urinary VEGF excretion during acute rejection to assess whether 
urinary VEGF levels were associated with rejection and with response to treatment. 
Of 215 patients enrolled, 67 had biopsy proven rejection. A statistically significant 
difference was demonstrated between the VEGF levels in patients with rejection 
(28.57 +-6.21 pg/ml) and without rejection (3.05 +-0.45 pg/ml). At a cut-off of 
3.64pg/umol creatinine the sensitivity of VEGF was 85.1% and the specificity was 
74.8%. Higher levels of VEGF predicted graft loss and steroid resistance. The 
authors concluded that VEGF levels in urine might have a role in monitoring 
transplant function and predicting rejection episodes (Peng et al., 2007). 
Research has also been undertaken to explore whether the genetic variations in 
VEGF expression influences the development of transplant rejection and has 
suggested that 2 specific genotypes are strongly associated with higher risk of acute 
rejection and have the potential to be useful markers of rejection risk (Shahbazi et 
al., 2002). 
 
1.12.8 Interleukin-22 
IL-22 is a member of the IL-10 cytokine family. It is produced by activated dendritic 
Cells and T cells and initiates innate immune response. It can be produced by Th17 
cells which are thought to play a key role in autoimmune disease and in inflammation 
and tissue injury. With the massive increase in the size of population of dendritic 
cells and T cells that occurs post transplantation it may be that IL-22 is a useful 
indicator of rejection within the renal allograft. The anti-CD20 antibodies that are 
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routinely used in transplantation also reduce the TH17 cell response so theoretically 
should decrease the levels of detectable IL-22, therefore, it may be that higher levels 
of IL-22 indicate those individuals who could require more intensive 
immunosuppressive therapy.  
 
1.12.9 Tumour Necrosis Factor-α (TNF-α) 
TNF-α is made by T-cells, NK-cells, macrophages and other cell types. It has a wide 
variety of functions but is centrally involved in inflammation and apoptosis. Early 
tissue expression of TNF-α has been shown to mediate neutrophil infiltration and 
injury after renal ishaemia-reperfusion (Donnahoo et al., 1999). It has also been 
shown that unilateral renal ischaemic injury induces bilateral TNF-α production and 
neutrophil infiltration through a TNF-α dependent pathway (Meldrum et al., 2002).  
A study in the UK looked at whether serum or urine levels of TNF-α could be used to 
discriminate between the causes of renal allograft dysfunction in order to avoid renal 
biopsy. TNF-α levels were measured at the same time as renal biopsy was 
undertaken to determine the cause of the transplant dysfunction but no difference in 
levels of TNF was seen between the causes of graft dysfunction (Newstead et al., 
1993).  
Early work suggested that TNF-α levels reacted to episodes of rejection and work 
undertaken to determine whether serum levels of TNF-alpha could therefore be of 
use clinically. Work looking at TNF-α levels during episodes of acute rejection found 
that plasma levels might have a role in the early detection and differential diagnosis 
of acute rejection. This hypothesis was based on the role of TNF-α as an important 
mediator of renal allograft rejection by causing depression of the intra-graft 
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thrombomodulin pathway and contributing to intra-graft fibrin deposition (Tsuchida et 
al., 1992). 
One study showed that TNF-α could predict episodes of rejection with a sensitivity of 
70-80% and a specificity of 89% (Dorge et al., 1994) and other studies have 
supported the potential role of TNF- α (Sonkar et al., 2013) however it has not been 
incorporated into clinical use. 
 
1.12.10 Interferon-γ (IFN-γ) 
IFN-γ is a cytokine that is critical for the innate and adaptive immune system, 
although those patients who have a primary deficiency of IFN-γ are normal. When 
expression of IFN-γ is disordered it is associated with autoimmune diseases. It is 
produced by natural killer cells and by CD4 and CD8 cells. It also stimulates 
secretion of IP-10 by monocytes, endothelial cells and fibroblasts. 
A French group have also looked at the expression of IFN-γ as a method of 
determining between subclinical and clinical glomerulitis. Biopsy specimens were 
compared between 22 patients with normal biopsy specimens at 3 months post-
transplant, 17 patients with clinically evident glomerulitis and 20 patients with 
subclinical glomerulitis. The expression of IFN-γ was significantly higher in patients 
with clinical glomerulitis than in subclinical glomerulitis, however the expression was 
also higher in patients with subclinical findings than those with normal biopsy results 
(Buob et al., 2011). 
It has also been suggested that following transplantation in patients with early graft 
function the ratio of IFN-gamma to IL-4 is significantly higher than in delayed graft 
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function as a resultant effect of changes to the resident T cell populations present in 
the graft and the characterisation of delayed graft function as a Th1 driven immune 
response (Loverre et al., 2011).   
Similarly in another study pre-transplant urine cytokine profiles to predict acute 
kidney rejection after transplant and demonstrated significantly higher levels IFN-γ in 
those who subsequently went on to develop rejection of the graft. The authors 
suggest this higher level of IFN may reflect an on-going non-specific Th1 immune 
response that is capable of amplifying the alloimmune response rapidly in the early 
post-surgery phase (Karczewski et al., 2010).  
The interferon pathway may also have a critical role in mediating renal 
ischaemia/reperfusion injury as demonstrated in animal models (Freitas et al., 2011).  
 
1.12.11 Cathepsin L 
Cathepsin L is a lysosomal protease involved in intracellular protein catabolism. It 
plays a role in antigen processing and growth regulation. It has been shown to have 
a role in antigen processing in turnover in intracellular and secreted proteins. Work 
examining transplant vasculopathy as an alloimmune form of vascular disease with 
enhanced neointimal formation and T-cell targeted allograft endothelial damage has 
also implicated Cathespin L (Soulez et al., 2010). 
Cathepsin L has been shown to have increased activity in the grafts of patients who 
have undergone transplant nephrectomy following chronic rejection (Paczek et al., 
1994). It is also implicated and under intense scrutiny for its role in the development 
of proteinuric kidney disease, specifically it seems Cathepsin L may have a critical 
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role in the mediating proteolysis in many forms of proteinuric renal disease (Sever et 
al., 2007). 
 
1.12.12 Immunoglobulin Light Chains 
Serum free light chain levels both kappa and lambda have been shown to vary 
amongst the renal transplant population in a way similar to that that occurs in the 
renal failure population i.e. that with increasing level of renal dysfunction the level of 
free light chain detectable increases (Sanchez-castanon et al., 2010).  
Serum free lights chains are primarily removed by catabolism in the proximal 
epithelial cells in the kidney. In normal kidney function this equates to approximately 
a serum half-life of between 2-6hrs. In severe renal failure the kidney’s ability to clear 
free light chains dramatically reduces and the main mechanism of clearance 
becomes the reticuloendothelial system so the half-life increases to 32h or more 
(Basanyake et al., 2011).  
This gives a potential role in monitoring the adaptive immune system using free light 
chains, although many facets of this potential application remain unexplored 
(Hutchinson and Landgren, 2011).  
 
1.12.13 Summary 
 
The major challenges of transplantation have progressed from those of early 
immunological loss to the long-term attrition of transplanted kidneys and to 
extending the long-term success of implanted kidneys. The question – Why a 
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kidney transplanted from a 20 year old donor only lasts 15-20 years in a recipient 
rather than the expected 40 plus years had it remained in situ - cannot be 
answered. 
The multi-factorial basis of this can be simplified into the functioning mass of the 
kidney and the loss of nephrons. This is based on the start point (chronic damage 
in the donor), peri-transplant events (acute injury in the donor and at retrieval) 
and recipient factors (acute and chronic injury). The ability to intervene prior to 
irreparable injury is a key aspect to preventing long-term damage. Currently 
monitoring of kidney injury in both donor and recipient is reliant on crude and 
imprecise methods, the mainstay being serum creatinine. This is particularly 
unsuited as a biomarker in kidney transplantation as it is delayed and represents 
established damage rather than an early indicator of acute insult that with 
intervention may allow reversal.  
As part of this MD I wish to test two major hypotheses: 
Hypothesis 1 
Acute kidney injury can be detected in deceased organ donors 
using biomarkers and can predict organ outcome once 
transplanted. 
Hypothesis 2 
Acute kidney injury post-transplant can be detected using 
biomarkers and help monitor transplant recipients. 
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The application of these hypotheses to organ allocation, peri-transplant organ 
manipulation (e.g. machine perfusion, normothermic perfusion, drug treatment) 
and post-transplant follow up may have major impact on clinical outcomes but 
also allow an easier, quicker and cheaper method of transplant care. 
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2 Chapter 2: Materials and Methods 
2.1 Developing an assay to measure the biomarkers 
In order to be able to reliably quantify the amount of biomarkers in each sample an 
assay is required. Whilst a variety of different types of assay are available the 
selection of the optimum assay, in this case Luminex, was based on a number of 
factors. The most important characteristic of the assay for this research was the 
ability to test for a number of different analytes on a sample of comparatively small 
volume. Whilst commercial ELISA assays are available for the analytes in question 
these are run in series on samples rather than in parallel on a single sample and 
hence the sample volume required would have been prohibitive. Similarly the cost of 
a commercially developed Luminex assay would have been high. However, an in-
house developed assay was deemed on balance the most logical solution. 
 
2.2 Principles of a Luminex™ assay 
Luminex™ assays allow the simultaneous analysis of up to 100 parameters in a 
single sample. This makes it ideal for running many different parameters on very 
small sample volumes. 
The technology is based around microspheres (spherical polystyrol particles) that act 
as the solid phase for the molecular detection reagents. The microspheres or beads 
have defined spectral properties. Each microsphere is labelled with a two distinct 
fluorescent dyes (red and infrared) which emit light in different regions of the optical 
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spectrum. The combination of these dyes allows the microspheres to be 
differentiated and identified on the analysis system.   
The microspheres are conjugated to protein-specific capture antibodies for the 
analyte in question. The microspheres are then exposed to the analyte in the sample 
and the target protein binds to the capture antibody that has been conjugated to the 
microsphere. A biotinylated detection antibody is then added which binds to the 
analyte. Streptavidin-conjugated fluorescent protein, R-Phycoerythrin (SAV-RPE) is 
added which binds to the biotinylated detector antibody. This means that a four 
member solid phase sandwich has been formed. The microspheres then pass 
through the Luminex™analyser which can then read the spectral properties of the 
beads and in conjunction with the amount of fluorescence from the streptavidin 
determine the amount of analyte present. 
 
Figure 2-1: Diagram of ELISA sandwich assay principle in the context of multiplexed assay 
(www.evetechnologies.com) 
 
2.2.1 Conjugation of proteins to microsphere beads 
In order for the Luminex™ assay to work the first stage in development is to 
successfully couple the capture antibody to the Luminex™ microsphere beads. This 
involves the capture antibody being re-constituted in an environment free from 
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sodium azide, Bovine Serum Albumin, Glycine, Tris or amine-containing additives as 
these interfere with the cross-linking. This is achieved by meticulous attention to the 
constituents of all components of reconsitution. In order to couple the protein to the 
microsphere bead the carboxyl group of the polystyrene bead is first activated with 
the carbodiimide derivative EDC (1-Ethyl-3-[dimethylaminopropyl]carbodiimide 
hydrochloride) to form an intermediate that is stabilised with S-NHS (N-
hydroxysulfosuccinimide). The intermediate then reacts with a proteins primary 
amine (NH2 groups) to form a covalent bond (amide linkage). This is shown below. 
 
Figure 2-2: Illustration of the chemical reaction that occurs during conjugation of capture 
protein to the microsphere beads  
 
In practice to achieve conjugation of the bead region a micro pellet is dispersed in a 
vortex using a mini shaker for 30s @2500/min. The microsphere pellet is then 
sonicated for 1 to 3 minutes   in an ultrawave sonicator to disperse the microspheres 
pellet. 200ul of the microsphere pellet is then placed into a micro well plate and the 
fluid is aspirated and the pellet is washed twice with 200ul of activation fluid (250ml 
distilled water, 3g NaH2PO4 (Sigma S0751) adjust to pH 6.2), and then re-
suspended in 200ul of activation fluid during the preparation of the coupling buffer. 
Coupling buffer is prepared by making fresh solution of sulpho-NHS (sigma 56485) 
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at 50mg/ml, fresh EDC (Sigma e6383) at 50mg/ml and mixing 10ul EDC + 10ul NHS 
+ 80ul of activation buffer for each well required. The activation buffer is then 
aspirated from the microspheres and 100ul of coupling buffer placed in each well. 
This is then incubated for 30mins in the dark at room temperature and the coupling 
buffer is aspirated and the beads washed with 200ul of PBS .100ul of antibody (at 
100ug/ml) is then added to each well and incubated for 3hrs in the dark at room 
temperature. Following this incubation the beads are washed with three times with 
storage buffer (200ml PBS, 2g BSA (Sigma A4503), 100ul Tween20 (Sigma P1379), 
0.2g Sodium Azide) and re-suspended in a total of 600ul of storage buffer. Following 
this the conjugated beads are stored at 4°C.  
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2.2.2 Antibodies used 
Antibody pairs and standards were supplied as follows: 
Table 2-1: Antibody pairs and standards as used in the final assay. 
Biomarker Capture antibody Detection antibody Standard 
NGAL R&D systems cat no: MAB17571 
Monoclonal Rat IgG 
R&D systems 
cat no: BAF 1757 
Polyclonal Goat IgG 
R&D systems 
cat no: 1757-LC 
recombinant human, 
murine myeloma cell line 
KIM-1 R&D systems cat no: AF1750 
Polyclonal Goat IgG 
R&D systems 
cat no:BAF1750 
Polyclonal Goat IgG 
R&D systems 
cat no:1750-TM-050 
recombinant human, 
murine myeloma cell line 
Cystatin C R&D systems cat no:DY1196 
MouseIgG 
R&D systems 
cat no:DY1196 
Mouse IgG 
Prospec 
cat no#: PRO-656 
recombinant human 
Cathepsin-L R&D systems cat no DY952 
Goat IgG 
R&D systems 
cat no DY952 
Goat IgG 
R&D systems 
cat no DY952 
recombinant human 
IFN-gamma Peprotech cat no: 900-k27 
rabbit origin 
Peprotech 
cat no: 900-k27 
rabbit origin 
Peprotech 
cat no: 900-k27 
recombinant human 
TNF-alpha Peprotech cat no: 900-k25 
rabbit origin 
Peprotech 
cat no: 900-k25 
rabbit origin 
Peprotech 
cat no: 900-k25 
recombinant human 
VEGF Peprotech cat no: 900-k10 
rabbit origin 
Peprotech 
cat no: 900-k10 
rabbit origin 
Peprotech 
cat no: 900-k10 
recombinant human 
IL-22 Peprotech cat no: 900-k426 
rabbit origin 
Peprotech 
cat no: 900-k426 
rabbit origin 
Peprotech 
cat no: 900-k426 
recombinant human 
IP-10 Peprotech cat no: 900-k39 
rabbit origin 
Peprotech 
cat no: 900-k39 
rabbit origin 
Peprotech 
cat no: 900-k39 
recombinant human 
Fractalkine Antigenix America cat no#: RHF 660 
Polyclonal rabbit 
Antigenix America 
cat no#: RHF 660 
Polyclonal rabbit 
Antigenix America 
cat no#: RHF 660 
recombinant human 
 
2.2.3 Determining the concentration of secondary antibody 
To determine the concentration of secondary antibody to be added, standard curves 
for each analyte were run with varying concentrations of secondary antibody were 
generated.  
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Figure 2-3: The effect of varying the concentration of secondary antibody on each biomarker 
to determine the optimum concentration showing the different standard curves produced. 
 
These curves are shown in figure 2-3. From these results the optimum concentration 
of secondary antibody was determined to be: 200ng/ml for KIM-1, IL-22, VEGF, IP-
10, Cystatin C, IFN-γ, TNF-α and was determined at 400ng/ml for NGAL and 
Fractalkine. Optimum concentration was decided on the basis of providing the best 
curve, particularly over the expected dynamic range of the assay which was 
determined from review of the available literature. 
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2.2.4 Determining the protocol steps 
The protocol for the assay development required modification in a number of wash 
and incubation steps to optimise. Following preparation of a 96 well plate with 
Luminex buffer 50ul of microsphere (1:100) was added to each well. 50ul of standard 
or sample was subsequently added and a first incubation step followed by wash step 
(incubation/wash 1). 50ul of detection antibody was then added and a second 
incubation step and wash stage performed (incubation/wash 2). 50ul of streptavidin 
phycoerythritin was added and a 30 minute incubation period and a wash step 
performed. Re-suspension in Luminex buffer and 30 seconds of agitation followed by 
analysis on the Luminex machine. 
The incubation/wash cycles (1&2) required offsetting the balance of maximising 
analyte detection with practicality of developing a practical and usable assay.  
Experiments to determine wash cycles and incubation times were determined on 
VEGF, IL-22, IP-10, Cystatin C and KIM-1. Once these had been established the 
protocol was then run on all analytes to ensure it worked. Particular note was made 
of the effect on cystatin C as MFI was noted to be very low and efforts were 
undertaken to improve this. 
 
2.2.5 Altering the duration of the first incubation step 
The basic protocol steps as detailed above were run using standard of 3 washes at 
each wash step of 200ul Luminex™ buffer and using a secondary antibody 
incubation step of 1.5hrs.  
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The duration of incubation of the initial incubation step was run at 4, 5 and 6 hrs and 
the effect shown below for 3 of the biomarkers (KIM-1, VEGF and IP-10). 
 
Figure 2-4: Effect of altering the duration of the first incubation step on MFI on the standard 
curve of KIM-1, VEGF, IP-10 to illustrate that a shorter incubation time described better 
standard curves. 
 
As can be seen from the above graphs, incubation time seemed to be optimal at 4 
hours or less. MFI were noted to be consistently very low for cystatin C (<70; not 
shown). These results seemed to indicate that running the assay with shorter first 
stage incubation time is beneficial not only from a practicality perspective but also 
from an assay optimisation. 
 
2.2.6 Altering the duration of the second incubation step 
The basic protocol steps as outlined above were used with 3 washes at each wash step of 
200ul Luminex™ buffer. In view of the effect of shortening the first incubation step as 
shown above the first incubation period was set at 2.5hrs. The second incubation step was 
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then altered to either 3,4 or 5hrs to determine whether this improved the performance of 
the assay. Data below is shown for KIM-1, IP-10 and VEGF. 
 
Figure 2-5: The effect of altering the duration of the second incubation step on the standard 
curves of 3 of the biomarkers (VEGF, IP-10 and KIM-1) demonstrating that lengthening the 
second incubation step did not benefit the assay. 
 
From the graphs above it can seen that there was little added benefit to lengthening 
the second incubation period and from a practical perspective shorter incubation 
periods make the assay more manageable.  
However, the results for cystatin C (not shown) were still extremely poor with 
maximum MFI’s achieved in the range of 50-80. It was decided to look at whether a 
property of the cystatin C was being affected by the cycles of washing or whether the 
antibody pair being used was just unsuitable for application to Luminex™ 
technology.  
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2.2.7 Determining the effect of one-step assay (removing wash steps) 
To determine whether the assay would show any benefit from being run as a one-
step assay a similar protocol to the basic protocol described above was utilised. 
However, after adding the standard to each well the secondary antibody was added 
immediately and a total incubation time of 4 hrs. allowed. After this standard wash 
cycles the addition of streptavidin followed. Results of this are shown below for 3 
biomarkers including Cystatin C. 
 
Figure 2-6: The effect of running the assay as a “one-step assay”. Results shown for KIM-1, 
VEGF. IP-10 and particularly Cystatin C demosntrating that undertaking the assay in this 
way signficiantly improved the MFI of Cystatin C. 
 
This method of performing the experiment is less reliable and has the potential to 
increase errors. However, it did show that for Cystatin C to work in this assay the 
incubation had to occur between the analyte, microsphere and secondary antibody 
simultaneously rather than as 2 separate steps. It was hypothesised that this was 
because Cystatin C exhibited tetramisation. 
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As the “one step assay” was determined to be less reliable overall it was decided 
that the standard for the protocol should include separate incubation steps for all 
biomarkers between the microsphere and the analyte, then the excess analyte 
washed away and the secondary antibody introduced except for Cystatin which 
seemed to be exhibiting tetramisation and so all steps would be combined only for 
Cystatin C. 
 
2.2.8 Standardisation of optimised protocol 
The new protocol based on the experiments detailed above was then tested to 
ensure that there was no interference between the biomarkers and that altering the 
steps of the protocol solely for cystatin C still allowed the protocol to work. Two 
standard curves were run for each analyte to ensure that the assay worked reliably. 
Results for each biomarker are shown figure 9. 
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Figure 2-7: Viability of the assay following the modifications made to the protocol including 
altering incubation steps and running Cystatin C in the format of a “one step” assay 
demonstrating that the assay overall works well although NGAL and Fractalkine levels were 
low (later determined to be due to antibody and standard degradation over time). 
 
The steps of the protocol are shown above to work well as can be seen above 
although the levels for particularly NGAL and Fractalkine were disappointingly low 
necessitating trial of different antibody pairs. This demonstrated improved MFI. 
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2.2.9 Exclusion of confounding factors 
2.2.9.1 Determining the effect of freeze and thaw cycles 
The nature of collecting samples, storing and then analysing them in batches 
inherently means they will be subject to freeze/thaw cycles. To determine the effect 
of freeze thaw cycles on the concentration of biomarkers, urine samples had to be 
made that contained artificial levels of the biomarkers as the majority of the markers 
are undetectable in urine under normal circumstances.  
Three separate samples of urine were used and artificially altered to contain IP-10, 
VEGF, KIM-1, NGAL, Fractalkine, TNF-α, IFN-γ, IL-22 and Cystatin C. Each sample 
was then subjected to either 1 or 2 or 3 or 4 freeze thaw cycles. After thawing, 
samples remained at room temperature for 30mins prior to re-freezing. Each freezing 
episode was for a minimum for 24hrs. The samples were then analysed to determine 
the effect of repeated freeze-thaw cycles. The results of this can be seen in the table 
below. Changes to the amount of biomarker measured are averaged for the 3 
different samples used. All percentage changes in measureable biomarker level are 
related to level measured from the sample that underwent only a single freeze thaw 
cycle. 
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Table 2-2: The effect of freeze thaw cycles on the levels of biomarkers present in the urine of 
3 patient samples. Values given are mean across the 3 samples to show the change in 
measurable level from the original sample. 
Biomarker Freeze/thaw x2 Freeze/thaw x3 Freeze/thaw x4 
IP-10* 0.5% ↓ 3.8%↓ 8.6%↓ 
VEGF* 39%↓ 31%↓ 52%↓ 
KIM-1 16%↑ 4%↑ 8.5%↓ 
NGAL 12%↓ 17%↓ 11.6%↓ 
TNF-alpha 7%↑ 13%↓ 33%↓ 
IFN-gamma* 20%↑ 1%↓ 6.3%↓ 
Cystatin C 30%↓ 31%↓ 33%↓ 
↓ represents a decrease in measurable level  
Results for Fractalkine and IL-22 were too low to be discriminatory and are therefore 
not shown. Results marked with * indicate those in which one patients levels were 
too low to be discriminatory and therefore only 2 patients data was used.  
These results show that VEGF and Cystatin C seem to be more prone to adverse 
effects of repeated freeze/thaw cycles and are relatively unstable, however, 
predominately the biomarkers variations are relatively small and while repeat 
freeze/thaw cycles will be avoided certainly 2 cycles seems to give results that are 
acceptable. 
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2.2.9.2 Determining the effect of urine pH 
Within the normal population urine pH can vary between pH 4-8. For the purposes of 
this assay it needed to be determined whether the pH of the sample affected the 
assay or the concentration of the biomarker and whether the samples needed to be 
buffered.  
Three separate patient samples of urine were artificially altered to contain 
measurable amounts of each of the biomarkers (as normally many of these are un-
measurable). The pH of the samples was assessed. The samples were then 
aliquoted and the pH adjusted to pH 4,5,6,7,8 and 9 (using 1M NaOH or 1M HCL). 
One aliquot of each sample at each pH was kept and either 25ul of Luminex™ buffer 
added or the sample was buffered with 25ul of 0.2M NaCCO3. Samples were then 
run according to standard protocol and the quantity of biomarker present compared 
to the baseline of the sample run without the addition at pH7. Samples were not 
corrected to urinary creatinine. 
Results of this experiment demonstrated that at the extremes of pH (i.e. pH 4 and 9) 
for all biomarkers the most noticeable difference in the amount of biomarker detected 
was seen. The addition of buffer showed no improvement in the variation and 
therefore the addition of buffer was determined as unnecessary. The differences in 
the amount of measurable marker at differing levels of pH could be related to either 
the artificial process of altering the pH of the samples or the effect of the pH on the 
assay mechanics or the effect of pH on the stability of the markers. However, 
although variations at differing pH were seen these were relatively small generally 
under 30% and may also therefore fall into assay variability. This mirrors work 
previously done looking at the pH stability of KIM-1(Pennemans et al., 2010). 
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2.2.9.3 Determining the effect of delay in freezing samples 
As the samples collected as part of the prospective trial are processed by a clinical 
lab they are subject to a delay in freezing after collection. This experiment was to 
determine the effect of delaying freezing on the amount of biomarker present in 3 
artificially created samples. Samples were frozen either immediately after collection 
or were allowed to be stored in a fridge at 4°C for 24hrs, 48hrs or 72hrs. They were 
then analysed as per the protocol outlined above.  
Table 2-3: The effect of the delay in freezing 3 samples on the measurable amount of 
biomarker contained within each sample. Separate aliquots of each of 3 patient samples 
were stored in in the fridge and frozen at: immediately, 24hrs, 48hrs and 72hrs following 
collection and then thawed and analysed. Results presented are mean values compared to 
the sample frozen immediately on collection. 
Biomarker 24hr delay 48hr delay 72hr delay 
IP-10 5%↓ 13%↓ 28%↓ 
VEGF 6%↓ 21%↓ 29%↓ 
KIM-1 18%↓ 40%↓ 38%↓ 
NGAL* 17%↓ 29%↓ 27%↓ 
TNF - α 33%↓ 70%↓ 76%↓ 
IFN - γ 36%↓ 57%↓ 68%↓ 
Cystatin C 15%↓ 7%↑ 23%↓ 
 
Fractalkine and IL-22 levels were too low to be accurately measured.  
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These results show that particularly for TNF-α and IFN-γ delay in processing and 
freezing the samples may have to be taken into account in analysing the samples as 
it may affect the results. For the other biomarkers the amount of effect that delaying 
freezing appears to have is smaller (<30%) and therefore is less likely to effect the 
interpretation of the results.  
2.2.10 Assay Variability 
To determine the variability of the assay on urine samples, 3 samples were altered to 
contain either: low, medium or high quantities of biomarkers. Each sample was then 
run 4 times according to standard protocol.  
Results of the Coefficient of Variation at different biomarker concentrations can be 
seen in the table 2-4. 
Table 2-4: The assay variability for each of the different biomarkers at low, medium and high 
concentrations of biomarker level showing the coefficient of variation of each biomarker at 
differing levels.   
Biomarker Low Medium High 
NGAL 6-13% 6-14% 15-23% 
KIM-1 2-5% 18-34%  
VEGF 15-32% 5-16% 4-29% 
IFN- γ 7-9% 2-19% 2-12% 
TNF-α 4-7% 3-8% 7-13% 
Fractalkine 16-23% 8-17% 6-30% 
IL-22  7-12% 10-24% 
IP-10 5-12% 9-23%  
Cystatin C 4-13% 4-18% 9-33% 
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2.2.11 Adapting the assay to add extra biomarkers 
The assay, whilst optimised, may be adapted to add extra markers without altering 
the existing setup. To test this a further biomarker of interest was added. Whilst the 
protocol steps remain unaltered it was felt important to exclude confounding factors 
to the new analyte. This can be seen below. 
Table 2-5: Effect of delay in freezing on three samples of urine containing Cathepsin, levels 
compared to the sample analysed having been frozen immediately on collection to 
demonstrate degradtion to sample with increasing delay in freezing. 
24hr delay 48hr delay 72hr delay 
27.5%↓ 9.3%↓ 2.1%↑ 
 
Table 2-6: Freeze/thaw characteristics of Cathepsin L underatken on three samples of urine 
to demonstrate the effect of multiple freeze thaw cycles as comapred to single freeze/thaw 
cycle in terms of levels of measurable cathepsin L. 
Freeze/thaw x2 Freeze/thaw x3 Freeze/thaw x4 
32.15↑ 13.3↑ 1.4↑ 
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Figure 2-8: Effect of varying the concentration of secondary antibody on MFI for Cathepsin L 
standard curves showing that optimum standard curves were generated with secondary 
antibody concentration of 200ng/ml. 
 
Following this the secondary concentration was set at 200ng/ml.  
The entire panel of biomarkers was run again to check that the addition of Cathepsin 
L did not affect the other biomarkers. Cathepsin L was also run as a single step 
assay (as for cystatin C) to see if this altered its performance but the standard curve 
was not improved so it was kept as two–stage assay as per the other biomarkers. 
 
2.2.12 Trouble shooting the assay 
Amongst the issues that became apparent during assay development was an issue 
with storage of the secondary antibodies. Through an iterative process of trial and 
error the optimum method of storing the secondary antibody was identified as being 
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in large volumes at -20°C although storage in small aliquots and storage in BSA and 
-80°C were trialled with poorer results. 
Similarly storage of standards required larger volumes (i.e. 0.5ml minimum quantity) 
and -20C°. 
Another issue that became apparent was the long-term stability of the standards and 
secondary antibodies was variable between the different biomarkers. This was 
addressed by assay quality control measures as detailed below.  
 
2.2.13 Assay Quality Control 
In order to monitor the reliability of the assay and ensure consistent results a number 
of strategies were used.  
Prior to any batch analysis of samples a standard curve was run to ensure that all 
antibody and standards were functioning as expected. MFI’s for the top of the 
standard curve were compared to previously run standard curves.  
On each plate two standard curves (8-point) were employed. This enabled 
calculation of the unknown samples biomarker concentrations using standard curves 
calculated from 2 curves.  
Each plate was run with two different control samples to control for both inter-plate 
variability and inter-batch variability. 
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2.3 Assessing KIM-1 levels using Lateral Flow device 
Renastick™ is a device that allows the quantification of the level of KIM-1 in urine in 
a near patient format. Renastick™ is a lateral flow device. These work by allowing 
the antigen to bind to travel down a porous surface and if present to bind to an 
indicator strip causing a colour change that becomes readable as a positive test 
result. The same technology is available in over the counter versions for example to 
screen for pregnancy.   
 
The lateral flow device can be used with a handheld reader to give a quantitative 
readout of the level of KIM-1. This has been validated by the manufacturer. The 
lateral flow device was employed on a sample of the deceased donor urine samples 
as described below as per manufacturer’s instructions/protocol.  
 
Samples of urine from the deceased donors were frozen prior to analysis, whilst the 
aim of the lateral flow is to measure levels in fresh samples at the patients bed side. 
To determine whether using the Renasticks on previously frozen samples would give 
comparable results a group of urine samples were analysed “fresh” and following 
and episode of freezing. The results of this demonstrated excellent correlation in the 
results with a Pearson r2 of 0.98and p value of <0.0001 as can be seen below. For 
analysis of the samples using the lateral flow device results are presented without 
normalisation to creatinine unless otherwise stated. 
   
  
90 
 
Figure 2-9: Correlation between KIM-1 levels in samples measured freshly or following 
freezing, by lateral flow device, demonstrating excellent correlation (Pearson r2 of 0.98and p 
value of <0.0001) and confirmed that freezing or analysing freshly does not alter the lateral 
flow reading. 
 
2.4 Statistical analysis methods 
Various statistical methods are employed throughout the analysis. These will be 
described in general and then with regard to the analysis they are used for. 
 
2.4.1 T-test 
T-test is used to determine whether two sets of data are significantly different from 
each other. This is carried out in both paired (when the same patient but samples 
from 2 different time-points are analysed) and un-paired (when different cohorts are 
compared) within the analysis. The test is used to prove or disprove the null 
hypothesis when the data is parametric. 
 
2.4.2 Mann-Whitney 
The Mann-Whitney U test is a non-parametric test of the null hypothesis and is used 
in the analysis when the data is non-parametric. 
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2.4.3 Contingency table analysis 
Contingency table analysis is undertaken to compared the frequency distribution of 
variables to determine whether a statistical difference occurs. 
 
2.4.4 Spearman rank correlation coefficient 
Spearman rank analysis is undertaken to determine whether there is an association 
between two variables where the data is non-parametric. The analysis can be 
undertaken on both continuous and discrete variables. 
 
2.4.5 Receiver operator curve (ROC) analysis 
ROC curves and the area under the curve (AUC) are used to determine whether a 
test has the ability to discriminate between individuals with a disease and those 
without. A test that has an AUC of 0.5 is not better than choosing at random and 
therefore worthless. A perfect test has an AUC of 1.0.  
 
2.4.6 Binary logistic regression analysis 
Logistic regression analysis is undertaken within the analysis to determine the effect 
of multiple variables where the outcome is either of two specific outcomes. It 
determines the relationship between a categorical dependent variable and one or 
more independent variables. 
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2.4.7 Chi squared 
Chi square test is undertaken on categorical data to determine the likelihood that 
differences seen between the results from sets of data arose due to random chance.    
 
2.5 Analysis of Deceased Donor Data 
2.5.1 Initial Analysis 
The samples for the deceased donors were analysed on the basis of outcome 
following transplantation. The samples were split into 2 groups overall: 
-­‐ Those samples from which both kidneys worked immediately 
(immediate/undamaged function group) 
-­‐ Those samples from which both kidneys had aberrant function either delayed 
graft function or primary non function (aberrant/damaged function group) 
For each of the markers analysed the results were analysed according to whether 
there was significant difference in the level of the marker between the2 groups using 
t-test (Mann-Whitney). 
 
2.5.2 Further Analysis 
Spearman Rank correlation analysis was undertaken to determine whether 
statistically significantly different biomarkers were associated with any of the other 
factors that were different between the two outcome groups. For example KIM-1 
levels were assessed to determine the level of association with age in the donors.  
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For those biomarkers that showed a significant difference between the two outcome 
groups ROC analysis was undertaken to determine the predictive ability of the 
biomarker to predict the outcome of aberrant early function. 
In order to allow for other clinical factors that might act in conjunction with the degree 
of underlying AKI determined by the biomarker level binary logistic regression 
analysis was undertaken using those factors that were statistically different between 
the two donor groups. This was conducted with using SPSS 19 (IBM, Chicago, Il) 
using effect method for binary logistic regression analysis.  
 
2.6 Analysis of Recipient Data 
Transplant recipient data was analysed in a number of ways. In order to determine 
differences between groups who did and didn’t get rejection Mann Whitney was 
performed (all data treated as non-parametric). This was undertaken comparing the 
whole cohorts of those who did get rejection and those who didn’t where the 
numbers were large enough to support this (HLAi data) and using paired t-test 
looking at the relative change in biomarker levels where numbers were smaller 
(ABOi data). Analysis was also undertaken between those recipients who developed 
delayed graft function and those who did not in the non-immunologically complex 
transplants using t-test. 
Similarly biomarkers that were significantly different between those recipients who 
did or did not develop rejection were also subject to ROC analysis. Contingency 
table analysis was undertaken using Chi square or Fishers exact test. 
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2.7 Sample collection for studies 
2.7.1 Deceased organ donor samples 
As part of a wider research project looking into circulatory organ donor outcomes 
934 potential cardiac/multi-organ donors families were approached to take part. In 
those that agreed a sample of urine was taken from the donor prior to organ 
donation. Samples were taken after confirmation of brainstem death but prior to 
procurement, then stored at -80°C and transported to the central research lab. Prior 
to analysis the specimens were defrosted, spun for 7 min at 3000rpm at 20°C to 
remove the cellular component and aliquoted before re-freezing at -80°C. 
 
2.7.2 Live organ donor samples 
All samples (both blood and urine) were processed by spinning for 7 min at 
3000rpm, aliquoted and stored at -80°C until batch analysis was undertaken. 
 
2.7.3 ABOi donor samples 
Blood samples were spun, aliquoted and serum stored at -40°C prior to analysis. 
 
2.7.4 HLA incompatible transplant samples 
Samples were stored in the NHSBT Histocompatibility and Immunogenetics 
laboratory in Birmingham following collection from patients at various time-points 
pre- and post-transplantation. The study had ethical approval and all patients 
consented to serum samples being taken and stored as part of the on-going 
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research study. All sera were separated from clotted whole blood and stored at -
40°C prior to testing.  
 
2.7.4.1 HLA Crossmatch methods 
These were undertaken by NHSBT but are included for completeness. 
2.7.4.1.1 CDC Crossmatch 
A total of 2ul of patient serum and 1ul donor cells (standardised to 2x106/ml) were 
mixed and incubated at 22°C for 60 minutes, with and without DTT. This was 
followed by addition of 5ul rabbit serum as a source of complement and then 
incubated for a further 60 minutes at 22°C. Cellular cytotoxicity was visualised using 
acridine orange/ethidium bromide cocktail under UV light microscopy. Anti-human 
globulin (AHG augmentation) is a means of enhancing the CDC match. It is a light-
chain specific antibody used to amplify the complement binding capacity of HLA-
bound IgG. It is sometimes used but not routinely and was not used in this cohort. 
2.7.4.1.2 Flow Cytometry Crossmatch 
A total of 25ul patient serum was incubated with 25ul donor cells (10x106/ml) at 22°C 
for 30 minutes. Cells were washed and then 100ul of goat anti-human IgG-FITC 
(Sigma- Aldrich, UK) was added and samples were incubated at 4°C in the dark for 
15 minutes. After washing with 100ul of mouse anti-human CD3-PE (Dako) was 
added for the T-cell crossmatch and CD19-PE (Dako) for the B-cell crossmatch and 
incubated for a further 15 minutes at 4°C in the dark. Samples were then 
resuspended in phosphate buffered saline (PBS) containing 2% bovine serum 
albumin (BSA) and analysed on a Becton Dickinson FacsCanto II flow cytometer. 
For each test sample the median channel shift for IgG-FITC was divided by that of 
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the negative control serum. The cut-off for positivity in HLAi transplant cases was 
defined as >2.5x the negative channel fluorescence. 
2.7.4.1.3 Single Antigen Bead (SAB) Analysis 
HLA class I and class II specific antibodies were detected using SAB manufactured 
by One Lambda (Canoga Park, USA). All assays were performed according to 
manufacturer’s instructions. For each case, the antibody specificities were 
determined prior to antibody removal therapy. Donor specific and third party antibody 
specificities were defined using a positive cut-off of 1000MFI, although knowledge of 
HLA epitopes was considered in each case to more accurately assign anti-donor 
reactivity. 
 
2.7.4.2 Desensitisation Protocol for HLA incompatible transplants 
Recipients underwent double filtration Plasmapheresis with the aim being to achieve 
a negative crossmatch prior to transplantation as previously described. In thos group 
the standard maintenance immunosuppression was mycophenolate mofetil 1000mg 
twice a day, tacrolimus 0.15mg/kg/day in two divided doses aiming for a target 
trough level of 10-15ug/l in the first month, prednisolone 20mg once a day, 
intravenous 500mg methylprednisolone intraoperatively and basiliximab 20mg on 
day 0 and day 4. 
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2.8 Sample analysis 
2.8.1 Analysis of deceased samples 
Urine samples were analysed initially at 1:4 dilution (diluted with Luminex™ buffer). 
Those samples that fell on the standard curve range too dilute were then re-run at 
1:2 dilution. For those samples that were too concentrated at 1:4 were run again at 
1:8. For each plate run two standard curves were included. The CV between 
standard curve points was then looked at between curves on each plate and 
between plates.  This can be seen below. 
Table 2-7: CV for biomarkers assessed in the analysis of the deceased donor urine samples 
showing acceptable CV for a research tool 
 KIM-1 NGAL VEGF IFN-γ TNF-α Fractalkine 
Cystatin 
C 
 CV averages across 
each point standard 
curve % (intrassay 
variability) 
4.4 - 
11.5 
8.2 - 
32 
5.0 - 
25.0 
10.0 - 
29 4 - 24.0 9.0 - 19 17.0- 34 
 CV averages across 
plates %  
(interassay 
variability) 
4.6 - 
9.7 
11.0 - 
30 
8.0- 
27 8.2 - 19 7.4 – 23 5.0 - 33 17.0 - 35 
 
Analysis was undertaken of the biomarkers with and without normalisation of the 
levels to urinary creatinine. 
 
2.8.2 Analysis of HLAi samples 
Serum samples were analysed for the panel of biomarkers as detailed previously 
using the Luminex™ based method. Serum biomarker levels were correlated with 
acute rejection occurring within the first 30 days after transplantation. Analysis was 
undertaken at 1 in 5 dilution and 1 in 100 dilution 
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Antibody mediated rejection (AMR) was suspected on decline in renal function, 
confirmed by the presence of donor specific antibody (DSA) and a biopsy showing 
the cellular changes of acute antibody-mediated rejection (peritubular capillaritis 
and/or glomerulitis) and negative for C4d (i.e. a biopsy ‘suspicious’ for AMR by Banff 
’07 criteria and confirmed in Banff 2013 as AMR). (Solez et al., 2008, Higgins et al., 
2010, Solez and Racusen, 2013) (Solez et al., 2008, Higgins et al., 2010, Solez and 
Racusen, 2013)  
 
2.8.3 Analysis of Renal Transplant Recipient samples 
Blood and urine samples were collected from transplant recipients pre-operatively, 
during the inpatient stay and at each out-patient clinic visit. Blood and urine samples 
were spun, aliquoted and stored at -80°C. Samples were analysed for the panel of 
biomarkers as detailed previously using the Luminex™ based method. Analysis was 
undertaken at 1 in 5 dilution and 1 in 100 dilution.  
 
2.8.4 Ethical approval 
For the study undertaken on non-antibody incompatible transplant recipients and on 
the live donors REC approval was gained REC reference: 10/H1206/65. All samples 
used from the Heart study and About-K were undertaken with ethical approval. 
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3 Chapter 3: Results 
 
3.1 Biomarkers in the assessment of deceased organ donors 
There are many difficulties in adequately assessing the potential deceased kidney 
donor. Often the patient’s history is incomplete and it is difficult to determine whether 
there is any underlying potential kidney damage. Similarly it is difficult to determine 
from external visual examination how successful the kidney transplant is likely to be. 
While biopsy specimens taken pre-transplant have been shown to have a role in 
identifying some underlying damage to the kidney these are often logistically difficult 
to arrange and result in extending the cold ischaemic time (Mazzucco et al., 2010). 
Whilst it is possible to identify some of the underlying chronic damage that may have 
accumulated, accurately determining acute kidney injury is more difficult. For this 
reason interest in biomarkers as a mechanism of predicting the potential outcome 
from the kidney donor has increased. It would be beneficial to have the knowledge 
about the degree of AKI in the donor before the process begins as part of the 
profiling of the donor. The advantage in identifying donor derived AKI is that 
immunosuppressive regimes could be tailored or recipient selection altered to 
attempt to optimize outcome and negate the impact of delayed graft function (DGF). 
DGF is associated with kidney injury and has been linked with acute rejection, 
increased biopsy requirements, longer post-transplantation hospital stays and worse 
1-yr outcomes for the graft (Quiroga et al., 2006, Dominquez et al., 2009, GIral-
Classe et al., 1998). 
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3.1.1 Study design 
The study was approved under the authority of National Health Service Blood and 
Transplant service.   
 
Of the 934 donors in the study assessed 917 (98.2%) of donated kidneys functioned. 
563 (60.2%) of donors provided kidneys that both showed immediate function. 133 of 
these donors were selected for analysis of urine samples for biomarker levels. 
Selection criteria for analysis were based on random choice of those samples with 
sufficient sample volume and the completeness of clinical data. 
 
The remaining 371 (39.7%) donors produced kidneys in which various presentations 
of aberrant initial function was observed. Both donated kidneys exhibited delayed 
graft function in 39 (4%) whilst 24 (2.5%) donors produced kidneys where one kidney 
showed DGF and one exhibited non-function. Urine samples from 32 (32/39=82%) of 
the former and 17 (17/24=70.8%) of the latter groups were analysed for biomarker 
levels and compared to the levels in the primary function group. For the purposes of 
this study the NHSBT definition of DGF of dialysis in the first week following 
transplant was used. 
 
308 (33.0%) of donors provided kidneys from whom one kidney had delayed graft 
function and one had immediate function were excluded from this analysis since it is 
probable that the difference between the outcomes of the two grafts resulted from 
events occurring after procurement and as such not detectable pre-donation. 
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Figure 3-1: Illustration of the selection of samples for inclusion within the study 
 
3.1.2 Method of analysis 
Samples of urine were analysed in 2 different ways.  
Urinary levels of β2M and albumin to creatinine ratio were measured by the Clinical 
Immunology Service of the Queen Elizabeth Hospital Birmingham. These were 
measured using the Roche Cobas c501 turbidimeter for urinary albumin, creatinine 
and B2M and an in-house Luminex™ multiplexed assay for the light chains. 
Urinary levels of VEGF, TNF-α, IFN-γ, KIM-1, NGAL, Cystatin C and Fractalkine 
were measured using the Luminex™ assay, developed as described in methods. 
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3.1.3 Donor demographics 
Table 3-1: Demographic details of the overall deceased donor pool in the study. 
Denominator values vary due to variations in available information from NHSBT database.  
Mean age 41.7 (range 16-65; SD 12.7) 
Female 41% (74/180) 
Male 59% (106/180) 
Cause of death  
• Hypoxic brain damage 8.8% (16/180) 
• Intracranial haemorrhage 65.6% (118/180) 
• Trauma 8.3% (15/180) 
• Intracranial thrombosis 2.7% (5/180) 
• Meningitis  1.1% (2/180) 
• Brain tumour 2.2% (4/180) 
Mean creatinine (mmol/l) 87.7 (range 35-303; SD 30.2) 
History of hypertension 16.7% (29/174) 
Need for CPR 17.7% (29/164) 
Use of inotropes 91.8% (156/170) 
 
The overall characteristics of the donors analysed can be seen in the table detailing 
the main causes of death. Donors had a mean age of 41.7. 
 
3.1.4 Kidney Donation data 
With the aim of identifying only AKI in the donors, rather than procurement damage, 
data relating the procurement procedure was examined. Organ procurement data 
demonstrated perfusion as good or fair in 99.7% (as subjectively assessed and 
documented by the retrieval surgeon at the time of retrieval). Surgical damage that 
was noted to have occurred during the procurement procedure included: stripping of 
the kidney capsule 2/346 (0.6%), haematoma evident on kidney 2/346 (0.6%) and 
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damage to renal vein 6/346 (1.7%). This demonstrated very low levels of surgical 
damage noted to have occurred at the time of procurement. 
 
3.1.5 Recipient Demographics 
Recipients had a mean age of 41.7 years. The differences between the recipients of 
the two outcome groups can be seen below (table 3-2). The only statistically 
significant difference between the recipients in the two groups was age; although 
different the actual difference was relatively small (40.4 vs. 45.5). 
Table 3-2: The differences between the recipients or either the kidneys from donors termed 
”aberrant early function donors” or “immediate function donors” in terms of demographics 
 
Recipients of kidneys 
from donors which both 
kidneys demonstrated 
Immediate function 
donors 
Recipients of kidneys 
from donors which 
both kidneys showed 
Aberrant early function 
donors 
p value 
Gender (%female) 41% (108/264) 32% (31/96) 0.144* 
Age (mean) 40.4 (n=263; CI 38.6-42.1)) 45.5 (n=96;CI 42.5-48.4) 0.004** 
Cause ESRF   
0.057*** 
overall 
• Diabetes 25% (66/266) 11% (11/98) 
• Glomerulonephritis 
+ IgA 
nephropathy 
9.8% (26/266) 14% (14/98) 
• Polycystic disease 8% (22/266) 7% (7/98) 
• Pyelonephritis 8.6% (23/266) 4% (4/98) 
• Other 19.5% (53/266) 22.4% (22/98) 
• Not reported 28.6% (76/266) 40.8% (40/98) 
* Fischers exact test, ** Mann Whitney, *** Chi square 
 
 
   
  
104 
3.1.6 Group analysis 
The differences between the characteristics of the two donor groups can be seen in 
the table below divided by the immediate function and the aberrant function group 
classification described above. P values were considered significant if <0.05. 
Table 3-3: Differences in characteristics between those donors whose graft displayed 
immediate function or aberrant function. 
 
Immediate function 
Donors (n=117) 
Aberrant function 
donors (n=49) 
p value 
Gender (%female) 37% (43/117) 53% (20/43) 0.0566*** 
Mean Age  38.5 (n=117) 50.4 (n=44) < 0.0001** 
Mean Creatinine 85.9 (n=124) 92.7 (n=44)  0.043** 
Cold Ischaemic time 15.8hrs (n=254) 16.4hrs (n=93) 0.399** 
Donor Hypertension 8.4% (11/131) 41% (18/44) <0.0001*** 
Cardiac arrest 23% (10/120) 16% (19/44) 0.3564* 
Treatment with 
inotropes 
93% (116/125) 89% (40/44) 0.5267* 
* Fischers exact test, ** Mann Whitney, *** Chi square 
 
As can be seen there were statistically significant differences between the two 
groups in mean age, mean creatinine and the presence of hypertension. This tallies 
with published data in terms of the outcomes from donors with higher terminal 
creatinine, history of hypertension and older age have poorer outcomes, so it is 
reassuring that this cohort is in concordance with data published previously. 
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3.1.7 Biomarker Panel Analysis 
To assess whether the previously described AKI biomarkers were different between 
the two groups of donors, suggesting that the presence of AKI might be different 
between the two groups, Luminex™ analysis was undertaken. The results of the 
biomarker testing via the Luminex™ method can be seen below and represented 
graphically in Figure 3-2. 
 
Table 3-4: Differences in urine biomarker levels between the groups (mean, 95% confidence 
intervals in brackets, statistically analysed using Mann Whitney) 
Biomarker Donors giving immediate functioning kidneys (n=133) 
Donors giving aberrant 
functioning kidneys (n=49) P value 
KIM-1 (ng/ml) 2.53 (2.0 – 3.0) 3.98  (2.9 – 5.1) 0.011 
NGAL (ng/ml) 92.17 (69.5-114.8) 92.63 (66.3-119) 0.309 
Fractalkine 
(ng/ml) 1.95 (1.7-2.2) 2.75 (2-3.5) 0.053 
VEGF (pg/ml) 357 (260-454) 726 (247-1206) 0.096 
IFN-γ (pg/ml) 63 (54-72) 64 (48-80) 0.710 
Cystatin C 
(ng/ml) 1083 (898-1268) 1218 (886-1549) 0.447 
TNF-α (pg/ml) 78 (57-99) 91 (51-131) 0.677 
β2-
microglobulin 
(mg/l) 
5.38 (9.1-15.4) 4.18 (5-11.4) 0.655 
Albumin: 
Creatinine 
mg/mmol 
38.7 (7.6-85) 14.7 (8.7-20.6) 0.210 
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Figure 3-2: Differences between urine biomarker levels in deceased donors between those 
whose grafts displayed immediate function and those with aberrant early function (median, 
25% to 75% percentiles). 
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Most candidate biomarkers showed no difference between the two groups. However, 
KIM-1 levels (Figure 3-2a) were significantly higher in the groups of donors whose 
grafts subsequently displayed aberrant early function (p=0.011).  Fractalkine levels 
tended to be higher in the aberrant group but failed to reach significance (p=0.053) 
(Figure 3-2c).  
 
To exclude the possibility that the concentration capacity of the donor kidney, either 
as a result of iatrogenic or intracranial events, had influenced urinary biomarker 
concentrations, levels were normalized to urine creatinine levels and re-analysed 
and expressed as biomarker: creatinine ratio as can be seen below. Only those 
biomarkers from whom the initial analysis showed a difference that was more 
significant than p<0.4 were normalised. 
 
Table 3-5: Biomarker levels following normalisation to urinary creatinine compared between 
the donors whose grafts displayed immediate function and those who displayed aberrant 
early function 
Biomarker 
Donors giving 
immediate 
functioning kidneys 
(n=133) 
Donors giving 
aberrant functioning 
kidneys (n=49) 
P value 
KIM-1: creatinine ratio 428.5 (357 – 500) 728.7 (533-925) 0.0068 
NGAL: creatinine ratio 20050 (15290-24810) 21660 (13840-29490) 0.5643 
Fractalkine: creatinine 
ratio 
402.7 (343-463) 701.3 (325-1078) 0.0038 
VEGF: creatinine ratio 211.9 (144-280) 225 (62-388) 0.7205 
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The KIM-1: Creatinine ratio and Fractalkine: Creatinine ratios were both significantly 
higher in the group with aberrant function. No significant difference was seen with 
the other potential markers. To further delineate the ability of these markers to 
predict outcome ROC analysis was undertaken. 
 
 
 
Figure 3-3: ROC analysis of deceased donor biomarker levels a) KIM-1 and b) Fractalkine: 
creatinine in predicting the outcome of aberrant early function demosntrating AUC of 0.62 
and 0.65 respectively. 
 
To determine whether KIM-1 and Fractalkine were associated with other variables 
Spearman rank correlation statistics was performed between donor age and donor 
creatinine and KIM-1 and Fractalkine. The results, shown below, revealed no 
association. 
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Figure 3-4: Correlation graphs of deceased donor markers (KIM-1 and Fractalkine) with 
donor age or donor creatinine 
 
3.1.8 Lateral Flow Assay 
KIM-1 was also measured using a point-of-care, lateral flow device (Renastick™, 
BioassayWorks, USA) as per manufacturers protocol along with a portable reader 
(Vaidya et al., 2009). This device is designed to be used at the bedside and for this 
reason the results generated were not compared as a ratio to urine creatinine as in a 
clinical setting this would be not be possible. 
To assess whether this assay could be used to measure KIM-1 it was employed on a 
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sample of the population comprised of aberrant early outcome donors (n=49) and 
immediate function outcome donors (n=40).  Results from this approach showed 
significant difference between the groups (p=0.03) with mean urine level in the 
former group of 8.0ng/ml and in the latter group 6.1ng/ml as can be seen below.  
ROC curve analysis showed an AUC of 0.63, similar to the multiplex assay. 
 
Figure 3-5:  Differences in urine KIM-1 levels as assessed by a Lateral flow device 
(Renastick™) in deceased donors (medians, 25-75% percentile shown). Results are not 
normalised to urinary creatinine. 
 
3.1.9 Binary logistic regression analysis 
The number of factors that interplay in the potential outcome of the graft suggest that 
a simple univariate analysis may be criticised for oversimplying the actual clinical 
real-world situation. For this reason a mechanism to try to integrate a number of 
potentially influential factors and determine the interplay between them is important. 
This is provided by Binary Logistic Regression analysis. Binary logistic regression 
analysis was undertaken using those variables that were identified as being 
statistically different between the donor groups of early dysfunction and good 
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immediate function (age, donor creatinine and history of hypertension). This was 
then combined in different permutations with either: 
a) KIM-1 level as determined by the Luminex™ assay 
Table 3-6: Results of binary logistic regression analysis using KIM-1 from Luminex™ and 
those variables previously identified as staistically signficantly different between the two 
outcome groups. 
Variables in analysis PPV NPV Sensitivity Specificity 
Donor age, donor creatinine, history 
hypertension, Kim-1 level 
0.68 0.83 0.45 0.93 
Donor age, history hypertension, Kim-1 level 0.70 0.81 0.40 0.94 
Donor age, history hypertension, donor 
creatinine 
0.61 0.80 0.37 0.92 
Donor age, history hypertension 0.64 0.80 0.35 0.93 
 
b) KIM-1 and Fractalkine normalised to urinary creatinine 
Table 3-7: Results of binary logistic regression analysis using KIM-1 normalised to urinary 
creatinine and those variables previously identified as staistically signficantly different 
between the two outcome groups. 
Variables in analysis PPV NPV Sensitivity Specificity 
Donor age, donor creatinine, history 
hypertension, Kim-1 level, Fractalkine level 
0.69 0.83 0.47 0.93 
Donor age, donor creatinine, history 
hypertension, kim-1 level 
0.67 0.83 0.47 0.92 
Donor age, history hypertension, kim-1 level, 
Fractalkine level 
0.68 0.82 0.43 0.93 
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c) KIM-1 as determined by lateral flow assay 
Table 3-8: Results of binary logistic regression analysis using KIM-1 from Lateral flow device 
(Renastick™) and those variables previously identified as staistically signficantly different 
between the two outcome groups. 
Variables in analysis PPV NPV Sensitivity Specificity 
Donor age, donor creatinine, history 
hypertension, Kim-1 level on lateral flow 
0.80 0.77 0.77 0.79 
Donor age, donor creatinine, history 
hypertension 
0.76 0.78 0.81 0.74 
Donor age, hypertension, Kim-1 on lateral 
flow 
0.84 0.81 0.82 0.83 
 
This analysis suggested that the most important donor characteristics predicting 
renal damage sustained pre-donation (essentially analogous to AKI) were age and 
history of hypertension as evidenced by their positive predictive ability. Surprisingly 
donor serum creatinine, although different between the two outcome groups, did not 
appear on logistic regression to differentiate between the outcomes. This concurs 
with the hypothesis suggesting that higher creatinine is not a reliable marker of 
eventual graft outcome. The addition of KIM-1 (measured by either method) 
increased the differentiation of aberrant early function from good immediate function 
donors as evidenced by the rise in positive predictive value.  
 
Binary logistic regression analysis of KIM-1 level as determined on lateral flow assay 
maintained the viability, in that addition of KIM-1 as measured by lateral flow method 
maintains its positive predictive value whilst using a more clinically applicable means 
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of investigation.  
 
The combination of factors that seems to be best identify those donors at risk of 
producing early dysfunction in the recipient are: the donor’s age, history of 
hypertension and urinary KIM-1 level on LFD. 
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3.2 Kidney biomarker changes in living organ donors 
A group of live donors was recruited in order to establish a control group for the 
effects of surgical intervention on biomarker levels. This was to ensure that any 
changes in biomarker levels seen in subsequent transplantation studies were truly 
reflective of changes resultant from the transplanted kidney rather than as a result of 
the surgery. 
3.2.1 Study design 
3.2.1.1 Recruitment and Sample collection 
This study was undertaken following national ethical approval. Patients undergoing 
live donor nephrectomy were approached to take part in the study to act as a control 
group. 15 patients were recruited. Blood and urine samples were taken at the 
following time points: pre-donation, 24 and 48hrs following donation.  
 
3.2.1.2 Demographics of cohort 
Table 3-9: Demographics of the live donor nephrectomy patients 
Characteristic Live donors (n=15) 
Age, years (mean) 51 (range 22-73) 
Male sex no. (%) 40% 
Operative time (mean) 104 mins 
Baseline  
-­‐ Creatinine mmol (mean) 72 
-­‐ GFR ml/min (mean) 80 
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The demographics of the cohort can be seen in the table above demonstrating mean 
age of 51 and average baseline GFR of 80ml/min which is in concordance with 
guidelines from the British Transplant Society.  
 
3.2.2 Biomarker Panel Analysis from living donors 
Urine and serum samples were analysed using the Luminex™ method described 
previously. 
Levels of IP-10, Fractalkine, IFN-γ and TNF-α were below the threshold for 
detection, as would be expected.  
Comparison at the time points of 24hr and 48hr to the pre-donation levels was 
performed for both urine and serum (figure 18). 
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Figure 3-6: Biomarker changes in live donor serum levels from pre-donation to 24hrs and 
48hrs following donation. 
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Figure 3-7:  Urinary biomarker levels at the time points of pre-donation, 24hrs following and 
48hrs after  live donor nephrectomy. Urine levels are not normalised to urinary creatinine.  
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As shown, levels of all biomarkers except Cathepsin L were not significantly different 
at 24hrs or 48hrs following organ donation.  
The lack of changes of biomarkers following surgery in this group is useful as they 
provide a point of comparison for the analysis undertaken on patients undergoing 
transplantation. By inference any changes seen in the transplant recipient population 
should be arising as a result of the transplanted kidney rather than as a result of the 
effects of surgical stress.  
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3.3 ABO incompatible transplants 
Transplantation across ABO incompatible blood groups has increased significantly 
since its inception using a desensitisation program in 1987 (Thielke et al., 2007). 
Whilst results, as previously described, are good and continue to improve they 
represent a different cohort of transplant recipients to the immunologically 
uncomplicated by virtue of the desensitisation program and often modified 
immunosuppressive regime they follow. Biomarkers that potentially detect or monitor 
the rejection process may, therefore, behave differently within this population. We 
aimed to determine whether biomarkers that had been suggested as markers of 
rejection in non-immunologically complex transplantation and as markers of acute 
kidney damage would have a clinical role in this sub-group of transplant recipients.  
 
3.3.1 Study design 
3.3.1.1 Recruitment and sample collection 
Patients undergoing ABOi transplantation were recruited to the ABOUT-K study (an 
observational, UK wide study evaluating antigen-specific antibody removal protocol 
for ABO-incompatible renal transplantation with national ethical approval). Blood 
samples were collected at time points including: pre-initiation of antibody treatment, 
post-treatment but prior to transplantation and at varying time points post 
transplantation as part of the ABOUT-K protocol.  
Overall 99 patient serum samples were available for analysis. All patients underwent 
ABOi transplantation between January 2009 and April 2012. Samples were collected 
from nine centres undertaking ABOi transplantation within the UK (Birmingham 
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Queen Elizabeth Hospital, Guys Hospital London, Northern General Hospital 
Sheffield, Royal Free Hospital London, University Hospital Wales Cardiff, St James 
Hospital Leeds, St Georges Hospital London, City Hospital Nottingham, Freeman 
Hospital Newcastle). 
Of the 99 patients recruited 17 (17%) displayed rejection in the first month following 
transplant. This was predominately cellular rejection (71%) with a small proportion of 
antibody mediated (18%) and mixed (12%). 
 
Table 3-10: Table demonstrating serum biomarkers levels in ABOi transplants between 
those patients who developed rejection and those who did not at various time points. Values 
are median. 
Biomarker Time point Rejection 
 
No rejection P value 
NGAL (ng/ml) Pre-transplant 7020 8058 0.49 
 Day 3 5426 4672 0.99 
 Day 5 6340 5669 0.44 
 Day 30 4160 3717 0.88 
KIM-1 (pg/ml) Pre-transplant 1233 1097 0.43 
 Day 3 1130 1036 0.46 
 Day 5 1203 1112 0.49 
 Day 30 1223 1034 0.05* 
VEGF (pg/ml) Pre-transplant 874 1028 0.27 
 Day 3 580 683 0.21 
 Day 5 603 628 0.89 
 Day 30 495 624 0.38 
IP-10 (pg/ml) Pre-transplant 168 174 0.61 
 Day 3 145 128 0.51 
 Day 5 143 147.5 0.78 
 Day 30 141 137 0.51 
Cystatin C (ng/ml) Pre-transplant 4022 4391 0.23 
 Day 3 4325 5285 0.36 
 Day 5 4761 3467 0.04* 
 Day 30 3452 3141 0.26 
Cathepsin L (pg/ml) Pre-transplant 6134 6503 0.19 
 Day 3 4773 4948 0.56 
 Day 5 5020 5007 0.95 
 Day 30 5357 4741 0.21 
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In view of the small numbers with rejection and the mixed nature of the rejection 
(combination of both cellular and antibody mediated) analysis was undertaken to 
determine whether examining the change in levels might differ between the two 
groups. 
In the group who developed rejection in the first month NGAL levels were not 
statistically different between the pre-transplant and the day 3 level, however in the 
group who did not develop rejection there was a drop in NGAL levels from pre-
transplant to day 3 (although this just failed to achieve significance). The range of 
values for the non-rejectors was much greater. Comparison was also made between 
NGAL levels those who developed rejection and those who did not at the time points 
of pre-transplant and at day 3 and this showed no difference between the two 
groups. This can be seen below. 
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Figure 3-8: Serum NGAL levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparson netween NGAL levels pre transplant between 
rejectors and non-rejectors and d) NGAL levels day 3 between rejectors and non-rejectors 
 
Although this failed to reach statistical significance it does seem to suggest that 
those patients who subsequently suffer from early rejection fail to clear their NGAL 
levels by day 3 post-transplant.  
A similar pattern is seen in KIM-1 with patients who subsequently develop rejection 
failing to demonstrate a drop in KIM-1 levels and those who do not develop rejection 
showing a fall in KIM-1 between the pre-transplant and the day 3 levels although it is 
worth noting the wide range of levels in the non-rejectors. 
a) NGAL in rejectors b) NGAL in non rejectors 
P value 0.3660 
c) NGAL pre transplant between 
rejectors and non-rejectors 
P value 0.9802 
d) NGAL day 3 between rejectors 
and non-rejectors 
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Figure 3-9: Serum KIM-1 levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparison between KIM-1 levels pre transplant between 
rejectors and non-rejectors and d) KIM-1 levels day 3 between rejectors and non-rejectors 
 
Interestingly in both groups VEGF levels fell at day 3, however, the fall was more 
noticeable in the non-rejectors although the range of levels was much greater than 
for rejectors. No statistical difference was seen between the levels either pre-
transplant or at day 3 between those who did or did not subsequently develop 
rejection.  
P value 0.0124 
b) KIM-1 in  non-rejectors a) KIM-1 in rejectors 
P value 0.2769 
P value 0.8055 
c) KIM-1 pre-transplant between 
rejectors and non-rejectors 
d) KIM-1 day 3 between rejectors 
and non-rejectors 
P value 0.4628 
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Figure 3-10: Serum VEGF levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparison between VEGF levels pre transplant between 
rejectors and non-rejectors and d) VEGF levels day 3 between rejectors and non-rejectors 
 
Although the decrease in IP-10 levels failed to reach significance as can be seen 
below (figure 3-11) The change in levels in the non-rejector group tended towards 
significance (p=0.0869) and this may have failed to reach significance in part due to 
the small number of patients with rejection. Although statistical significance was not 
reached the degree of change was still different to that in the rejectors group where 
no change was seen. Levels directly compared between the rejectors and non-
rejectors at pre-transplantation and day 3 were not different suggesting that it is not 
P value 0.0085 
a) VEGF in rejectors b) VEGF in non rejectors 
c) VEGF pre transplant between 
rejectors and non-rejectors 
d) VEGF day 3 between rejectors 
and non-rejectors 
P value <0.0001 
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just that there are higher levels for example pre-transplant between the two groups 
that could explain the trend.  
 
Figure 3-11: Serum IP-10 levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparison between IP-10 levels pre transplant between 
rejectors and non-rejectors and d) IP-10 levels day 3 between rejectors and non-rejectors 
 
A similar pattern is also shown for Cystatin C with a significant drop in levels on day 
3 from the pre-transplant levels in those who did not develop rejection whereas the 
rejection cohort failed to show a change in Cystatin C level. Again, comparison of the 
levels pre-transplant demonstrated that there was no significant difference 
suggesting that the change is not purely a product of different starting levels. The 
P value 0.6102 P value 0.5093 
P value 0.6512 P value 0.0869 
a) IP-10 in rejectors b) IP-10 in non rejectors 
c) IP-10 pre transplant between 
rejectors and non-rejectors 
d) IP-10 day 3 between rejectors 
and non-rejectors 
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observed drop between pre-transplant levels and day 3 levels may be reflective of 
the ability of the transplant not developing rejection to clear cystatin C effectively. 
 
Figure 3-12: Serum Cystatin C levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparison between Cystatin C levels pre transplant between 
rejectors and non-rejectors and d) Cystatin C levels day 3 between rejectors and non-
rejectors 
 
For Cathepsin L both groups showed significant decreases in levels from pre-
transplant to day 3 although the difference was more marked in the non-rejector 
cohort than in those patients who subsequently developed rejection. 
c) Cystatin C pre transplant 
between rejectors and non-
rejectors 
P value 0.4488 
P value 0.2314 
P value 0.0002 
P value 0.3620 
a) Cystatin C in rejectors b) Cystatin C in non rejectors 
d) Cystatin C day 3 between 
rejectors and non-rejectors 
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Figure 3-13: Serum Cathepsin L levels in a) ABOi rejectors and b) ABOi non-rejectors pre-
transplant and day 3 and c) comparison between Cathepsin L levels pre transplant between 
rejectors and non-rejectors and d) Cathepsin L levels day 3 between rejectors and non-
rejectors 
 
For all the biomarkers there was a greater decrease in the levels between the pre-
transplant levels and the day 3 levels that was more marked in those who did not 
develop rejection. Speculatively this is likely to be due a combination of factors; it 
may be that the rejection process is detectable at this very early time period by these 
biomarkers prior to an effect on creatinine or it may represent better function within 
those kidneys that do not develop rejection enabling them to clear the biomarkers 
more effectively.  
c) Cathepsin L pre transplant 
between rejectors and non-
rejectors 
P value 0.0302 
P value 0.1940 P value 0.5545 
P value <0.0001 
d) Cathepsin L day 3 between 
rejectors and non-rejectors 
a) Cathepsin L in rejectors b) Cathepsin L in non rejectors 
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3.4 HLA incompatible transplants 
With the ever growing waiting list for transplantation and re-transplantation, inevitably 
the population of potential kidney recipients who are highly sensitized will increase. 
Transplantation across previously impossible HLA barriers (defined as 
transplantation against a positive crossmatch) is now considered routine in many 
centres, however, it is still limited by poorer long term outcomes, perhaps in part due 
to the effects of rejection with rates of rejection between 12-53% (Gloor et al., 2010, 
Thielke et al., 2009, Vo et al., 2010, Haririan et al., 2009, Higgins et al., 2009). In this 
sub-group of transplantation recipients, with a very high rate of rejection, any 
mechanism of reducing and potentially improving long term outcomes would be 
extremely useful.  The potential of biomarkers to help elucidate those at higher risk 
could also be invaluable in increasing the use of transplantation across this 
immunological barrier. 
3.4.1 Study design 
3.4.1.1 Patient Selection 
Retrospective analysis was performed on a library of sera from ninety-four HLA 
sensitised patients who underwent HLAi renal transplantation between 2003 and 
2012. Patients were selected for inclusion in the University Hospital Coventry and 
Warwickshire program if they had current reactivity with donor-specific HLA 
mismatches as measured by complement dependent cytotoxic crossmatch (CDC), 
flow cytometric crossmatch (FC) or single antigen bead (SAB) assay as undertaken 
by the NHSBT Histocompatibility and Immunogenetics laboratory (for further detail 
see methods). 
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Patients undergoing HLA incompatible transplantation between 2003 and 2012 at a 
single centre were recruited. Serum samples were taken at time points of prior to 
transplantation (including prior to therapy to achieve desensitisation), day 1 following 
transplantation and at day 30 after transplantation.   
 
Donor Specific Antibody levels prior to pre-transplant antibody removal, day 1 post-
transplant and at 30 days following transplant were also recorded. Donor specific 
antibody levels were also correlated with the rejection occurring during the first 30 
days following transplantation and to serum biomarker findings. 
 
3.4.2 Demographics of the cohort 
Between 2003 and 2012, 94 patients underwent HLAi transplant of whom 44 (46%) 
developed acute rejection in the first month. The mean time to onset of rejection was 
4.2 days. The majority of organs were from live donors with only 8 from deceased 
organ donors. There were no significant differences between patient demographics 
although differences between pre-transplantation antibodies were seen between the 
group of rejectors and non-rejectors. Baseline demographics between those patients 
who did or did not develop rejection can be seen in the table below (Table 3-11). 
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Table 3-11: Comparison of demographic data between those with rejection and no rejection 
of the HLA transplants 
 No rejection (n=50) Rejection (n=44) P value 
Age mean (median, range) 41.8 (42, 18-67) 44.2 (43.5, 22-68) 0.38 
Sex (M:F) 18:26 21:29 1.0 
Time on dialysis (mean, months) 70 79 0.37 
Time on waiting list (mean, months) 53 59 0.41 
Donor specific antibody Class I – 25 
Class II – 14 
Both – 11 
Class I – 17 
Class II – 11 
Both - 16 
0.30 
Number of mismatches (Median) 3  (0-5) 3 ( 1-5) 0.24 
Number of previous transplants 
(median) 
1 (0-3) 1 (0-3) 0.80 
Crossmatch CDC+/FC+/SAB+ 11 
23 
16 
13 
24 
7 
0.18 
CDC - /FC+/SAB+ 
CDC-/FC-/SAB+ 
DSA MFI 
       Total pre-transplant (mean, range) 
       Day 1 (mean, range) 
 
 
6574 (221-36360) 
2963 (97-17760) 
 
8594 (124-33730) 
3278 (75-13950) 
 
0.123 
0.630 
Creatinine Day 1 (mean and 95%CI) 331 (284-378) 369 (318 -420) 0.262 
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3.4.2.1 Initial Biomarker Analysis 
Analysis was undertaken between the cohort who went on to reject in the first 
30days and those who did not for each of the time points. The results of this for all 
biomarkers can be seen below. 
a) Comparison between biomarker levels in rejectors and non-rejectors pre-
transplantation  
 
Figure 3-14: Comparison of serum biomarker levels in HLAi transplant recipients pre-
transplantation between those who subsequently developed rejection and those who did not. 
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b) Comparison between biomarker levels in rejectors and non-rejectors at day 1 
following transplantation 
 
 
Figure 3-15: Comparison of serum biomarker levels in HLAi transplant recipients day 1 
between those who subsequently developed rejection and those who did not 
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c) Comparison between biomarker levels in rejectors and non-rejectors at day 
30 following transplantation   
 
Figure 3-16: Comparison of serum biomarker levels in HLAitransplant recipientsat day 30 
between those who subsequently developed rejection and those who did not 
   
  
134 
Levels for IFN-γ, TNF-α, IL-22 and Fractalkine were below the level of detection to 
be accurately assessed in the cohort. 
Overall analysis revealed no significant differences in biomarker levels either pre-
transplant or at 30 days following transplant.  
However, significantly elevated levels of NGAL (p=0.005, means of 7657 ng/ml vs. 
10080 ng/ml) and IP-10 (p=0.0001, means of 54.5pg/ml vs. 74.2pg/ml) were seen on 
day 1 in recipients who subsequently rejected in the first 30 days (Figure 3-15). 
There was no significant difference between the two groups with regards to other 
evaluated biomarkers. Analysis was also undertaken to determine the relationship 
between levels of NGAL and IP-10 and demonstrated a weak correlation indicated 
by a Spearman r of 0.25 (CI 0.45-0.44, p=0.015). This suggested a weak association 
between the two levels. 
ROC analysis was undertaken to determine the ability of Day 1 NGAL and IP-10 to 
predict rejection within the first 30 days. This demonstrated an AUC of 0.67 and 0.73 
respectively (Figure 3-16). At a cut off of 50pg/ml IP-10 demonstrated a specificity of 
72% and sensitivity of 70% for predicting rejection. At a cut off of 6300ng/ml NGAL 
demonstrated a specificity of only 56% and but a sensitivity of 86% for predicting 
rejection. At this level NGAL also had a negative predictive value of 82% (PPV 63%) 
suggesting that it might have a role as a screening test i.e. in a clinical setting if the 
NGAL level was under 6300ng/ml it would be reassuring that rejection was unlikely.  
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Figure 3-17: ROC analysis of HLAi biomarkers for IP-10 and NGAL 
 
DSA levels were compared to biomarker levels at the time points described 
previously. DSA levels at these time points did not correlate with levels of any of the 
biomarkers at the same time points. Analysis was also undertaken using a pre-
transplant DSA cut off MFI of 2000 which demonstrated significantly higher chance 
of rejection in those patients with a pre-transplant DSA level above 2000 (28% vs. 
54% p=0.048). There was no significant association between IP-10 and NGAL with 
DSA levels on day 1 (p=0.77, p=0.133 respectively). 
Levels of IP-10 and NGAL were also correlated to the time of onset of rejection to 
determine whether the magnitude of biomarker level on day 1 was predictive of the 
timescale of rejection. Spearman r for NGAL was -0.21 with a p value of 0.17 
indicating no significant association between the level of NGAL on day 1 post-
transplant and the timeframe for developing rejection. For IP-10 a Spearman r value 
of -0.354 was generated with a p value of 0.02 demonstrating that the level of IP-10 
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on day 1 post -transplant is weakly associated with the timeframe for developing 
rejection. 
Patients who subsequently developed acute rejection demonstrated a trend towards 
higher rates of delayed graft function (DGF) than those without rejection, but this was 
not significant (38% vs. 25% p=0.47). NGAL and IP-10 levels have been suggested 
to be elevated in DGF in other cohorts and the differences between levels in this 
cohort were examined to ensure this was not causative in the association with acute 
rejection. Analysis revealed that NGAL and IP-10 levels were not significantly 
different on day 1 between those who had DGF or primary function overall (p=0.32 
and 0.12 respectively). Similarly, no significant differences were seen between 
NGAL or IP-10 levels in those patients with rejection whether they developed DGF or 
not (p=0.99 and 0.51 respectively). This implies that the elevated levels of IP-10 and 
NGAL on day 1 in those who later develop rejection are not a function of their higher 
rates of DGF. Whilst there is evidence in the literature suggesting that NGAL is 
associated with DGF the lack of association between IP-10/NGAL and DGF in this 
study could be explained because of the high proportion of live donors and the lower 
percentage of DGF in this population. 
  
   
  
137 
3.5 Biomarkers in the monitoring of renal transplant recipients 
To provide a counterpoint for the results of the biomarker assessments in the 
immunologically complex transplant recipient a comparable group of non-
immunologically complex recipients were studied. A prospective trial was established 
with ethical approval for recruitment of both living donor transplant recipients and 
deceased donated kidneys. Although recruitment was prospective all analysis was 
undertaken as a batch retrospectively. 
 
3.5.1 Study Design 
3.5.1.1 Patient recruitment  
Patients undergoing both live and deceased renal transplantation were approached 
to take part in a prospective study to determine the use of Biomarkers for monitoring 
renal transplant function. Blood and urine (where possible) samples were taken both 
pre-operatively and post-operatively as an in-patient and then at regular scheduled 
out-patient follow up appointments.  
Results were analysed comparing the levels of the biomarkers at pre-transplant and 
day 1 post transplant, pre-transplant and at day 30 post-transplant to act as control 
group for the changes seen in the immunologically difficult transplants. Biomarker 
levels were also compared between the groups who developed delayed graft 
function to determine whether levels on day 1 post-transplant were significantly 
different and able to predict delayed graft function. 
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3.5.2 Recruitment and outcomes 
36 patients were recruited who proceeded to successful kidney transplantation. Of 
the 36 patients 30 were transplanted from deceased donors (24 DBD and 6 DCD) 
and 6 were live donors. The mean recipient age within this group was 42.5 and the 
mean donor age was 49. Of the 36 patients 13 were female (36%) and 23 were male 
(64%). 
Within this cohort 2 patients developed rejection, giving an acute rejection rate of 
5.5%. The lower than perhaps anticipated level of rejection means that planned 
analysis of the samples to determine their ability to predict rejection is unfortunately 
not possible. However, this does mean they are able to act as a control for those 
changes seen in the immunologically complex transplants. 
Below can be seen the biomarker changes seen in serum between pre-transplant 
samples and day 1 post-operative samples demonstrating no significant difference 
between the two time points (figure 3-18). In this analysis the 2 patients with 
rejection were excluded.  
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Figure 3-18: Serum biomarker levels in immunological straightforward transplants at pre-
transplant and day 1 showing no statistically significant differences. 
 
With the cohort 14 patients had delayed graft function (defined as the need for 
dialysis in the 7 days). This gives a DGF rate of 39% permitting analysis of 
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biomarker predictors of delayed graft function. Day 1 Serum and urine biomarkers 
were compared between those who developed delayed graft function and those who 
did not. These results can be seen below (figure 3-19).  
 
Figure 3-19: Differences in serum day 1 levels of biomarkers in immunologically 
uncomplicated transplants between those recipients with DGF and those with immediate 
function 
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Figure 3-20: Differences in urine day 1 levels of biomarkers in immunologically 
uncomplicated transplants between those recipients with DGF and those with immediate 
function. 
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This demonstrated that serum levels of cystatin C and urine levels of KIM-1 and 
NGAL were statistically different on day 1 between those recipients with delayed 
graft function and those with immediate function. Whether these markers are 
detecting underlying AKI that leads to DGF or are a surrogate marker of decreased 
renal clearance is difficult to say. 
To determine the predictive ability of those markers that were identified as being 
statistically different between the two groups of those who did and didn’t develop 
delayed graft function ROC analysis was undertaken. The results of this can be seen 
below (Figure 3-21). 
 
Figure 3-21: Graphs demonstrating ROC analysis of DGF predictors for serum Cystatin C 
and urinary NGAL and urinaryKIM-1 
 
As can be seen day 1 serum Cystatin C has excellent predictive ability for delayed 
graft function and urinary levels of KIM-1 and NGAL also have good predictive power 
although with the caveat that many of those patients with delayed graft function will 
not have passed any urine on day 1. 
At a cut off of 1807ng/ml serum Cystatin C demonstrated a sensitivity of 80% and a 
specificity of 83%. At a cut off of 1421 pg/ml urinary KIM-1 displayed a sensitivity of 
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75% and a specificity of 81%. At a level of 8517ng/ml urinary NGAL showed 
sensitivity of 80% and specificity of 71%. It may be that the value of biomarkers in 
this setting is as a screening tool; at a cut of level of 1500ng/ml Cystatin C has a 
negative predictive value of 89% suggesting that day 1 levels may prove an excellent 
screen for DGF. 
Predictors of delayed graft function were also assessed in the original 60 HLAi 
transplants (ABOi transplants were excluded as the earliest post-transplant sample 
available for analysis was day 3).  
From the cohort of HLAi transplants 12 patients demonstrated delayed graft function 
from the total with available outcomes of 54. This gives a rate of delayed graft 
function of 22%. This is lower than the rate in the immunologically uncomplicated 
transplants probably reflecting the higher proportion of living donors in the HLAi 
cohort.  
Analysis of biomarker levels on day 1 between those recipient who did or did not 
have DGF can be seen below (Figure 3-22). 
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Figure 3-22: Differences between biomarker levels in the HLAi transplant group on day 1 
between those with or without DGF 
 
As can be seen in this HLAi cohort of patients serum Cystatin C levels were not 
statistically different between those with DGF and those with immediate function 
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which is in contrast to the immunological straightforward transplants. Interestingly in 
this cohort Cathepsin L and IP-10 were statistically different. ROC analysis 
demonstrated AUC of 0.75 for Cathepsin L and 0.78 for IP-10. It is difficult to 
interpret the IP-10 results in isolation as of those patients with DGF in the HLAi 
cohort 50% also had rejection and as previously demonstrated IP-10 levels are 
elevated on day 1 in those patients who subsequently develop rejection. Cathepsin 
L, however, was not predictive of rejection so may be a more reliable predictor of 
delayed graft function in this cohort. 
Levels of Cathepsin L were compared within those patients with delayed graft 
function between those who also had rejection and those who only had delayed graft 
function. This can be seen below (Figure 3-23).  
 
Figure 3-23: Graph to demonstrate differences in Cathepsin L level between those patient 
with DGF and either rejection or no rejection 
The graph demonstrates that levels of Cathepsin L are much higher in the group with 
pure delayed graft function rather than the mixed picture of rejection and delayed 
graft function, although this failed to reach significance perhaps due to the small 
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numbers in each group (n=4 in the pure DGF group, n=6 in the combined group). 
This is in contrast to IP-10 levels which are very similar between the two groups 
(p=0.81).  
Levels of biomarkers were also compared between the HLA rejectors, HLA non-
rejectors and the non-immunologically complex transplants at the time-points pre-
transplantation, day 1 and day 30. 
Results of this can be seen below for NGAL, IP-10 and Cystatin C (figures 3-24, 3-25 
& 3-26). 
Figure 3-24: Differences between serum NGAL levels in the HLAi transplant recipients with 
rejection, HLAI transplant recipients without rejection and “normal” transplant recipient 
groups 
P=0.024
P=0.60
P=0.02
P=0.007
P=0.05
P=0.23
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NGAL levels were significantly higher pre-transplant in the HLAi group who 
subsequently developed rejection when compared to the normal transplant group 
whereas the HLAi group who did not develop rejection were no different from the 
normal group. 
At day 1 post-transplant levels of NGAL amongst the HLA rejection cohort were 
higher than the normal transplants and HLAi with no rejection were no different from 
the normal transplants. At 30 days following transplant NGAL levels in the “normal 
transplants” were significantly lower than either the HLA rejectors or the HLA non-
rejectors whose levels had equalised (as shown in Figure 3-24). 
 
Figure 3-25: Differences between IP-10 levels in the HLAi transplant recipients without 
rejection, HLAi transplant recipients with rejection and “normal” transplant recipient groups 
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The reasons for this marked difference could be speculated to relate to the presence 
of donor specific antibodies in the HLAi group, however, more study would be 
needed to confirm this. 
IP-10 levels were significantly higher in normal transplants than in the HLA group 
whether they subsequently developed rejection or not. At Day 1 post-transplant IP-
10 levels were significantly lower in the HLA non-rejection group whilst the levels 
amongst the normal and HLA rejector levels were not different. At 30 days following 
transplant HLA group without rejection were still significantly lower than either the 
HLA rejection group or the normal group (as shown in Figure 3-25). 
 
Figure 3-26: Differences between Cystatin C levels in the HLAi transplant recipients and 
non-antibody incompatible recipient groups 
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Cystatin C levels were not significantly different between the HLAi rejectors and the 
normal transplants pre-transplant but the levels in the HLA group without rejection 
were significantly lower than the normal or HLA rejection group. At Day 1, although 
not statistically different, levels in the HLA rejectors were higher than the normal 
transplants levels. This rise was sustained at 30 days following transplant and did 
reach significance (as shown in Figure 3-26).  
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4 Chapter 4: Discussion 
4.1 Deceased donor biomarker analysis 
 
Deceased organ donation is complex and many events may impact upon outcome 
including any chronic and acute kidney injury pre-existing in the donor at the time of 
donation. This includes factors relating to the donor, the organ retrieval process, the 
cold ischaemic time and the recipient factors as discussed earlier. Most donors have 
a history of complex, and often traumatic, events preceding donation that carry the 
risk of AKI. 
 
Chronic damage is a non-modifiable factor that leads to long-term, suboptimal renal 
function after transplantation but may not impact on the graft’s initial functional 
status. Hence a graft with chronic damage may achieve primary function but 
longevity and the baseline function may be suboptimal. By contrast AKI is more likely 
to be associated with delayed, or rarely, primary non-function. The combination of 
AKI in a chronically damaged kidney is poor for the outcome but difficult to 
distinguish in practice.  
Nevertheless, assessing the level of AKI at the time of donation can be difficult. In 
the situation of the critically ill patient urine output and creatinine can be difficult to 
interpret. Creatinine is recognised as a poor marker of AKI as plasma levels are 
influenced by non-renal events affecting its generation, distribution and 
excretion(Port et al., 2002, Star, 1998).  
When offered a kidney for transplant the surgeon has few tools to discriminate a 
“good” from a “bad” kidney. 
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This study cohort assesses the ability of the previously identified AKI biomarkers to 
predict which donors have sustained AKI as reflected in post-transplant graft 
dysfunction. This is not always a clear relationship as many events between 
donation and the early post-transplant period can induce AKI. However, these 
variables were controlled for (as much as possible) allowing donor-derived AKI to be 
assessed in isolation. Hence, all donors were deemed suitable for cardiac donation, 
were young with low probability of chronic renal damage. There were no obvious 
adverse events reported at procurement or implantation and donors were excluded 
when events appeared most likely to have occurred i.e. where only one donated 
kidney showed aberrant function - suggesting a post-donation event. 
 
Even in a cohort of optimized, near ideal donors, in whom the process of 
procurement appears uncomplicated, 6.5% of donors still produce two kidneys in 
which post-transplant dysfunction was observed.  
 
The availability of a point-of-care test for KIM-1, that could be routinely performed on 
candidate donors and predict recipient kidney transplant outcome, could facilitate 
greater matching of donor-recipient pairs and increase the availability of the organ 
pool by identifying those organs with AKI rather than poor function due to irreversible 
chronic damage.  
 
Machine perfusion may have a role in determining the quality of organs and failure of 
parameters to improve has been shown to correlate to higher discard of organs 
previously (Patel et al., 2012). Similarly histological examination of biopsy tissue can 
help determine chronic damage, but it has been suggested that significant problems 
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can occur with the examination of biopsy tissue and lead to higher than necessary 
discard rates (Kasiske et al., 2014). With pressure to keep cold ischaemic times as 
low as practicable both these options are not necessarily ideal in every case and a 
immediate indicator to perhaps indicate which kidneys would benefit from further 
evaluation would be useful.      
 
The point of care lateral flow device (Renastick™) allows the user to easily assess at 
the patient’s bedside the level of KIM-1 in the urine. This raises the possibility of 
incorporating the KIM-1 level into the assessment of the potential donor on the 
intensive care unit, particularly in combination with other known potential risk factors 
for poorer outcomes following organ donation. This could help donor management, 
perhaps aiming to modify those risk factors that are modifiable such as cold 
ischaemic time, machine perfusion or recipient selection. Whilst clearly further 
studies need to confirm these findings it may be that the lateral flow assay may be 
the catalyst that drives the transition for biomarkers from the research laboratory to 
widespread clinical adoption.  
Crucially whilst KIM-1 in deceased donors did seem to have predictive ability for 
DGF it’s role in directly predicting long term outcome is currently not known.  
 
4.2 Biomarker changes following Live donor nephrectomy 
Patients undergoing laparoscopic donor nephrectomy show no changes to biomarker 
levels either in urine or serum as a result of the surgical intervention. This allows the 
inference to be made that any changes that are then seen amongst the transplant 
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population reflect changes as a result of the transplanted kidney rather than as a 
result of the physiological stress of surgery.  
Previous authors have suggested that donor nephrectomy leads to cytokine and 
biomarker changes as a result of hypertrophy and up regulation within the remaining 
kidney (Yap et al., 2012). This wasn’t seen in our cohort of patients. Possible 
reasons for this may be due to the shorter operative time in our cohort or different 
operative technique (hand assisted laparoscopic donor nephrectomy vs. fully 
laparoscopic) used in the published literature.  
 
4.3 Biomarker changes in the HLAi transplant population 
This study demonstrates that the biomarker IP-10 has a good ability to predict 
rejection in the first 30 days in this group of transplants, as evidenced by the AUC of 
0.73. Whilst levels of NGAL were significantly different between the two groups its 
ability to differentiate was inferior, with an AUC of 0.67. However, both merit further 
evaluation as they may have differing roles as screening tools. 
The analysis of biomarkers of rejection usually involves the comparison of biomarker 
levels at the time of diagnosis of rejection (e.g. upon biopsy for rising creatinine) with 
biomarker levels in a cohort with stable renal function. This strategy does not identify 
the rejection process at an earlier time point than standard current practice. The 
ability of a single biomarker or a panel of biomarkers to predict rejection earlier than 
current methods would expedite diagnosis and treatment of the episode. It may also 
identify those patients at higher risk of rejection and guide surveillance. Since 
increased glomerular margination can be detected as early as 30 minutes following 
perfusion in biopsy specimens of those who later go on the develop rejection, it is not 
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unreasonable to suggest that a more peripheral investigation such as a blood test 
could detect changes that similarly predict rejection soon after transplantation 
(Higgins et al., 2010) 
The correlation statistics between IP-10, NGAL and the timeframe for developing 
rejection suggests that the higher levels of IP-10 on day 1 may be associated with 
more rapidly developing rejection. 
Interestingly, in contrast to our results a 2005 study showed high pre-transplant 
levels of serum IP-10 in immunologically uncomplicated transplants was correlated 
to worse graft outcomes and rejection in the first 30 days whilst our pre-transplant 
levels were not different (Lazzeri et al., 2005). However, in our study cohort day 1 
post-transplant levels of IP-10 did show good predictive ability for rejection within the 
first month. IP-10 levels at day 30, following treatment of the rejection episode, 
normalised to the same as the levels of those without rejection suggesting that IP-10 
may also be able to demonstrate sufficient immunosuppression has been achieved. 
The difference in IP-10 levels demonstrated in this and other cohorts also the raises 
the possibility of IP-10 as a potential target or pathway, as well as a marker of 
immunological activity and this certainly merits further study.  
DSA levels have been previously shown; pre-transplant, to be suggestive of 
development of rejection. Work undertaken demonstrated higher rates of rejection 
amongst patients with pre-transplantation DSA’s of above 2000u (Higgins et al., 
2009).  Within our cohort rates of rejection were significantly higher in the group 
whose pre-transplant antibody levels were above 2000 (28% vs. 54% p=0.048). 
However, levels at other time points provided no additional information in predicting 
rejection. This is probably because of the combined effects of antibody removal prior 
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to transplantation and absorption of antibody by the kidney immediately following 
transplantation. It is important to consider that these biomarkers can be predictive of 
rejection when detected as early as 1 day post-transplant. In the majority of our 
cohort at this time point there is very little, if any, detectable DSA, due to reasons 
outlined earlier such as antibody absorption via epitopes expressed on the kidney 
and it is unknown whether this may also have an indirect effect on biomarker levels. 
As such the level of DSA in the very early post-transplant period is of little predictive 
value, thus augmenting the importance of the discovery of new informative 
biomarkers. 
 
4.4 Biomarker levels between antibody incompatible vs. antibody 
compatible 
The differences between the HLAi group who reject, the HLAi group who do not and 
the non-antibody incompatible transplants are interesting. At the pre-transplant 
timepoint the HLA rejection group NGAL levels are higher than non-antibody 
incompatible or HLA non-rejectors and this is sustained at day 1 suggesting that 
NGAL is reflecting the underlying reactivity or response to the immune mediated 
process. Perhaps more interestingly is that at day 30 there is no difference between 
the HLA rejection and no rejection group whilst the normal transplant levels are 
much lower. It is difficult to explain exactly why these differences exist. It would be 
interesting to explore them further to determine whether they reflect the on going 
difference between the HLA transplant recipient population and the non-
immunologically complex transplants. It could be hypothesised that the NGAL levels 
reflects a higher basal level of neutrophil trafficking within the HLA grafts (as a result 
   
  
156 
of the mismatch) that might be causing sub-clinical damage, however, without further 
study this remains purely speculative.  
The cystatin C changes show higher levels in HLA rejectors at day 1 and this is 
sustained at day 30 although HLA non-rejectors levels are similar to those of the 
normal transplants. This seems to suggest that the damage caused by the rejection 
episode may cause sustained or long term damage that isn’t detected by 
conventional methods.  
The differences in the IP-10 levels are the most interesting as their trends are 
different from the other markers. IP-10 being a tissue expressed chemokine ligand 
supports its role in activated T cell recruitment. IP-10 secretion is upregulated by 
fibroblasts, monocytes and endothelial cells in response to IFN-γ. It has been shown 
to have functions including promoting recruitment and adhesion of T cells.  At all 
time-points the levels of IP-10 are lower amongst the HLA non-rejectors than the 
normal transplants perhaps reflective of the heavier burden of immunosuppression. 
Whilst the levels in HLA rejectors are lower pre-transplant than the normal patients 
levels they are much higher at day 1 although not statistically significant. At day 30 
the HLA no rejection group’s levels are much lower than either of the other 2 groups.  
What this seems to suggest overall is that there are notable differences in the 
biomarker profile between the HLA and the “normal” transplants. This means that 
when considering the use of biomarkers in the HLA group it maybe that they will 
need to be utilised in a way that is fundamentally different from their application in 
other potential transplant groups. For example it may be that comparison with 
baseline “normal” levels of biomarkers in the HLA group will have to be used as the 
benchmark rather than levels from the “normal” transplant population. It will also be 
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important to bear these differences in mind on other biomarker research that may not 
segregate the immunologically complex from the immunologically uncomplicated 
transplants. This may in part be due to the effects of previous transplants in the 
sensitisation process. 
Historical attempts to predict antibody mediated rejection in HLAi transplants using 
standard cross-match and IgG levels were unsuccessful. They did however 
demonstrate that detection of preformed C4d antibody did link to outcome (Bartel et 
al., 2013), although levels of soluble CD30 and CD27 in the HLAi renal transplants 
failed to find an association with episodes of acute rejection (Hamer et al., 2010).  
 
4.5 Biomarker changes in ABOi transplant recipients 
Despite a large cohort of patients undergoing ABOi transplantation the levels of 
rejection in the cohort are low when compared to the frequency of rejection in the 
HLAi population. This may suggest that blood group incompatibility is easier to 
overcome than HLA incompatibility. 
From a clinical perspective, in terms of the utilisation of this technique to increase the 
numbers of living donors, this is excellent. It does mean that levels of rejection in this 
cohort were low from the perspective of analysis of biomarker levels, particularly as 
the levels of antibody mediated rejection were so low. 
Analysis initially undertaken compared the entire cohort changes in a manner similar 
to that used for the HLA transplants but this failed to demonstrate any differences. 
However, analysis examining the change in levels in each separate group revealed 
some very interesting findings. 
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Amongst those patients who did not reject in the first month levels of NGAL, KIM-1, 
VEGF, IP-10, Cystatin C and Cathepsin L all decreased between the pre-transplant 
levels and levels at day 3 (IP-10 levels did not reach significance although they 
approached it). However, in the patients who did experience rejection, levels either 
did not show a reduction of significance (NGAL, KIM-1, IP-10 and cystatin C) or 
showed a less significant reduction (VEGF and Cathepsin L). 
This raises the possibility the markers NGAL, KIM-1, IP-10 and Cystatin C could 
have a role in predicting rejection in the ABOi transplants. Interestingly these are the 
same markers (other than the inclusion of KIM-1) that showed promise in the HLA 
analysis. 
It could be hypothesised that in those patients who do not go on to develop rejection 
adequate immunosuppression has been achieved as evidenced by the fall in the 
levels of the biomarkers, raising the possibility that monitoring of levels and their 
changes could allow tailoring of immunosuppression.  
Absence of a fall in levels may be important and raises the question of whether at 
this early time-point post transplantation that rejection is affecting the kidney or the 
biomarkers are acting as surrogate markers of immune activation within the graft or 
systemically. In order to determine this non-immunologically mediated injury would 
have to be compared to determine whether that caused similar changes to marker 
levels.    
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4.6 Non-antibody incompatible transplants and predicting Delayed 
Graft Function 
As mentioned previously the occurrence of acute rejection in the recruited cohort 
was so low that any analysis looking for indicators of rejection amongst the 
biomarkers is impossible. This is common to many transplant studies using acute 
rejection and large cohort studies are undoubtedly necessary. However, the changes 
in marker levels do provide interesting counter point for those changes seen in the 
more immunologically complex transplants.  
The nature of the recipient recruitment also ensured that a greater proportion of the 
patients recruited were deceased donor transplants and therefore rates of delayed 
graft function in the “normal” group are comparatively large. This enabled the 
assessment of these biomarkers in the setting of predicting delayed graft function 
from the recipient perspective.  
As can be demonstrated the only serum biomarker for delayed graft function was 
cystatin C which had an AUC of 0.82 at day1 post-transplant. This has potentially 
useful clinical implications as a serum test which may offer advantages over a urine 
test as it is not subject to the same potential confounders as a urine marker e.g. 
oliguria post operatively, underlying native urine produced by damaged kidneys and 
dilution resultant from intravenous fluid shifts. The potential negative to a serum test, 
compared to urine test, is that levels may be influenced by dialysis and some 
patients undergoing transplantation do require dialysis immediately post-operatively 
as a result of hyperkalaemia produced by the surgery.  
Analysis of the urine demonstrated that KIM-1 and NGAL levels were also predictive 
of DGF (AUC 0.76,0.78). With the availability of a point of care urine test for KIM-1 
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levels it is conceivable that it might be possible to determine at a very early time-
point post-transplant how likely the patient is to develop DGF. Whilst direct 
mechanisms to intervene and change the clinical course of delayed graft function are 
currently unavailable this is an area of growing interest. 
The analysis of the HLAi cohort predictors of delayed graft function is difficult to 
interpret due to the high incidence of rejection in those with delayed graft function. 
This is especially true of IP-10 whose levels have been shown to correlate to 
rejection on day 1. Although difficult to analyse, as the number are small, Cathepsin 
L, does appear to differentiate DGF on day 1 in the HLA group. While drawing hard 
and fast conclusions seems premature it could be hypothesised that this difference 
in Cathepsin L reflec a combination of the differing neointimal changes already set in 
motion within the kidneys and the differing degrees of apoptosis within those kidneys 
with DGF and those with immediate function. 
It is interesting that Cystatin C, which showed good predictive power in the “normal” 
transplants failed to differentiate in the HLAi transplants. This suggests that findings 
between the different groups of transplants (immunologically uncomplicated, ABOi 
and HLAi and possibly even live donor vs. deceased donor) may well display 
different biomarker changes, suggesting differing underlying processes or affects. 
This means that any finding in one group needs to be verified in the other rather than 
purely accepted as being generalizable to the entire transplant population.  
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5 Limitations of study 
 
Perhaps one of the biggest limitations with the study is that all samples were stored 
and analysed in batches retrospectively. This raises a number of issues, not least 
that some of the biomarkers may have degraded over time so levels may not entirely 
reflect levels in fresh samples. Whilst the experiments detailed before aimed to 
demonstrate the effects of freeze thaw and delay in freezing the effect of long term 
storage which some of the samples have been subject to is more difficult to assess. 
The only way round this is prospectively analysed fresh samples. The numbers of 
participants in the ABOi and the HLAi study groups are large, however, this has 
meant that collection over a protracted period was necessary (particularly for the 
HLAi). This not only raises the storage issue but seemingly small changes to 
treatment protocol or immunosuppressive regimes over the period of recruitment 
may be present. 
The deceased donor biomarker work was undertaken only on DBD cardiac donors 
who represent a very specific group of organ donors, so prior to any firm conclusions 
being drawn extrapolation to a full clinical trial would be essential. 
The non-antibody incompatible transplant analysis is limited by recruitment numbers. 
It would be extremely interesting to examine biomarker changes in this cohort with 
regard to rejection, however, the low rates of rejection mean that for meaningful 
statistical analysis to be undertaken significantly larger numbers of patients 
undergoing transplantation would need to be recruited. Despite this they still act as a 
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good counterpoint to the changes in the other groups although they are a 
hetergenous group. 
A further limitation of the study is that for the non-antibody incompatible transplant 
group and the live donor group the urine biomarker levels were analysed without 
normalising to the urinary creatinine. There remains debate on when or how urinary 
biomarkers should be normalised to urinary creatinine as in some situations, for 
example established AKI, it may be that non-normalised biomarker levels may more 
accurately represent the clinical situation (Ralib et al., 2012). However, it may be that 
normalisation of the biomarker levels to creatinine might have provided a different 
insight in these groups and, therefore, it remains a limitation. 
Renal transplant recipients represent a very heterogenous group with a widespread 
aetiology of renal failure and other co-morbidities. Inherently this makes it difficult to 
generalise and biomarker work needs to be carried out across much larger study 
populations than has been undertaken to date so that any differences as a result of 
underlying disease process rather than the transplant outcome can be controlled for.  
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6 Development of the work from this thesis  
 
1. Role of KIM-1 in assessing deceased organ donors 
Following the identification of urinary KIM-1 as a mechanism of identifying AKI in 
cardiac organ donors (DBD) and its correlation to early graft outcome this should be 
assessed in a wider range of organ donors. Most notably it would be good to 
extrapolate this work in the form a prospective clinical trial encompassing all organ 
donors. If the hypothesis that KIM-1 can help identify AKI holds true for a wider 
donor cohort then the use of a point-of-care test to routinely identify this would 
potentially be extremely useful and could find a role in routine donor assessment.  
 
2. Role of IP-10 in predicting rejection 
The changes in IP-10 levels between rejectors and non-rejectors both in the HLAi 
group and the ABOi are very interesting. More work looking into whether IP-10 is a 
biomarker or actually a potential target in the process would be worthwhile, however, 
it would be useful to set up a prospective clinical trial stratifying HLAi patients into 
low and high risk of rejection on day 1 post-transplant and to potentially modify their 
surveillance.  
3. Role of biomarkers in identifying delayed graft function 
Given the demonstration of both urinary and serum biomarkers that can predict 
delayed graft function a trial using some novel interventions to try to ameliorate the 
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delayed graft function would be useful to demonstrate a real function and it may be 
that changes to biomarker levels actually provide standardised endpoints for such 
research. 
 
In this research I have demonstrated that Biomarkers can help inform on renal 
transplants in a number of settings. A possible role in the identifying DBD donors 
whole have incurred AKI which may translate to DGF has been identified. Similarly 
potential markers in immunologically complex transplants that may help predict early 
rejection have been suggested.   
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8 Appendix A 
Characteristics of an Ideal Biomarker  
It should be visible early, prior to histopathological changes, and should be 
indicative after active damage 
It should be sensitive, but it should also correlate with the severity of damage 
It should be accessible in the peripheral tissue; in the case of the kidney, for 
example, it should be measurable in either the blood or the urine 
It should be analytically stable in tissue so it can be measured after 
It should be translational; that is, it should bridge across species. 
It should be associated with a known mechanism.  
A biomarker should be able to localize damage 
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9 Appendix B  
 Published work arising from this thesis:  
 
Urinary biomarkers of acute kidney injury in deceased organ donors--kidney injury 
molecule-1 as an adjunct to predicting outcome.  
Clin Transplant. 2014 Jul;28(7):808-15. 
Field M, Dronavalli V, Mistry P, Drayson M, Ready A, Cobbold M, Inston N. 
 
The use of NGAL and IP-10 in the prediction of early acute rejection in highly 
sensitized patients following HLA-incompatible renal transplantation. 
Transpl Int. 2014 Apr;27(4):362-70 
Field M, Lowe D, Cobbold M, Higgins R, Briggs D, Inston N, Ready AR. 
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Summary
Acute rejection is a significant problem for patients undergoing HLA-incompati-
ble renal transplantation, affecting between 12 and 53% of patients. Any mecha-
nism of detecting rejection in advance of current methods would offer significant
benefit. This study aimed to evaluate whether serum biomarkers could predict
rejection in HLAi transplants recipients. Sera from 94 HLAi transplant recipients
from a single centre were analysed for a panel of biomarkers including: NGAL,
KIM-1, IP-10, cystatin C, cathepsin L and VEGF. Biomarker levels pre-opera-
tively, day 1 and at day 30 post-transplant were correlated with the development
of early rejection. Significantly higher levels of IP-10 and NGAL were seen on day
1 following transplant in those patients who developed acute rejection (P < 0.001
and 0.005) and generated AUC of 0.73 and 0.67, respectively. No differences were
seen for the other biomarkers or at the other time points. In this study cohort, IP-
10 and NGAL have demonstrated good predictive ability for the development of
acute rejection at a very early time point. They may have a role in identifying
patients at higher risk for rejection and stratifying immunosuppression or surveil-
lance.
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Urinary biomarkers of acute kidney injury
in deceased organ donors – kidney injury
molecule-1 as an adjunct to predicting
outcome
Field M, Dronavalli V, Mistry P, Drayson M, Ready A, Cobbold M,
Inston N. Urinary biomarkers of acute kidney injury in deceased organ
donors – kidney injury molecule-1 as an adjunct to predicting outcome.
Abstract: Background: Deceased kidney donors are increasingly
“marginal,” and many have risk factors for acute kidney injury (AKI)
that may impact on subsequent renal transplant outcome. Despite this,
determining the presence of AKI at the time of deceased organ donation
remains diﬃcult.
Methods: Urine samples from 182 brainstem dead multi-organ donors
(all of whom donated hearts that were transplanted) were analyzed for a
LuminexTM panel of biomarkers linked with AKI. This included KIM-1,
NGAL, IFN-c, TNF-a, cystatin C, Fractalkine and vascular endothelial
growth factor. Levels were correlated to early renal transplant outcomes,
most speciﬁcally delayed graft function.
Results: Donor urinary KIM-1 levels were signiﬁcantly higher in donors
whose kidneys displayed aberrant early function (p = 0.011). Fractalkine
levels showed a trend toward elevation in such donors but uncorrected
this did not attain signiﬁcance. No correlation occurred with the
remaining biomarkers.
Conclusions: KIM-1 appears to show promise as a marker for AKI in
deceased cardiac organ donors. The availability of a lateral ﬂow device
(RenastickTM) for KIM-1 that also demonstrates higher urinary KIM-1
levels in donors whose kidneys show aberrant initial function (p = 0.03),
makes KIM-1 a potential indicator of AKI that may merit further
evaluation for its application at the donor bedside.
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